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Abstract 
Polymorphism (including solvated solid forms) is relatively common among steroids. 
Understanding the physical properties of each polymorph/ solvate is important for evaluating 
their relative stability and dissolution rates (related to bioavailability). In pharmaceutical 
industry powder X-ray Diffraction (XRPD), complemented by thermal methods, is the most 
widely used technique for characterising solid forms. However, these methods do not directly 
provide molecular-level information. Solid-state NMR here plays an important leading role. 
A number of polymorphs and solvates of two steroids (androsterone and finasteride) have been 
studied. Solid-state NMR and XRPD were used to characterise the hemihydrate form and the 
anhydrous form 1 of androsterone. XRPD was also used to study the transformation between the 
hemihydrate and the anhydrous form at room temperature as a function of time. Furthermore, 
the 13C CPMAS spectra of the two forms were assigned by applying specialised NMR pulse 
sequences. 
A number of solid forms of finasteride have been described in the scientific and patent 
literature. Combined characterisation by solid-state NMR and X-ray diffraction has identified 
deficiencies in the patent literature, reflecting the limitations of characterisation based on XRPD 
alone. For instance, one of the patented finasteride "polymorphs" was proved to be a dioxane 
solvate hydrate. Solid-state NMR and single-crystal XRD have been used to define the structure 
in a number of newly prepared finasteride solvates. The solvates were found to be all 
isomorphous with each other as well as with another solvate reported in the literature. They 
appear to be bis (finasteride) monosolvate monohydrates. Preliminary proton spin-lattice 
relaxation measurements were done on the solvates and on form 11 (anhydrous). It is suggested 
that the relaxation is driven by reorientation of the methyl groups rather than by solvent 
dynamics. A new form X was characterised by solid-state NMR though the sample is of 
unknown origin. TGA and DSC experiments were also carried out on the various forms. 
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Chapter 1: Introduction 
Chapter 1.: :n:ntroduction 
1.1 Polymorpbs 
Structural properties of polymorphs have constituted an important research area with 
rapid development over the past few decades. A number of definitions are reported for the 
phenomenon of polymorphism1'2• The simplest and fairly classical definition for polymorphs 
is that they are solid forms of different crystal structures of the same chemical substance 
which produce indistinguishable solutions when dissolved. A number of annotations are used 
for labelling polymorphs; the most commonly used are Arabic or Roman numerals. It has 
been commented that "the number of known polymorphic forms for a given compound is 
proportional to the time and money spent in research on that compound"2• It is very important 
to distinguish between true polymorphs and other solid forms like solvates (see the following 
section). Mixing up the definitions of solid forms develops considerable confusion in the 
literature, hence complicating follow up on the research area. 
1.2 Solvates/ Hydrates 
Solvates (including hydrates) are different from true polymorphs because they include 
additional solvent molecules in the crystal structure in addition to the base molecule or host. 
Solvates have been also termed as pseudopolymophs although this terminology is not 
recommended1• Stoichiometric solvates, especially hydrates, are of comparable importance to 
that of polymorphs in the pharmaceutical industry because solvation or desolvation can occur 
during the manufacture formulation and storage of drugs. Some solvates are desolvated 
without destroying the basic structure whereas in other cases desolvation can lead to break 
down of the structure. Non-stoichiometric solvates are also reported to be of an interese (e.g. 
hydrates of tartrate, sildenafil and thiamine hydrochloride). The characterisation of 
pharmaceutical hydrates must be sufficient to provide confidence that the behaviour of the 
hydrate is predictable and reproducible. It is reported for example that the smaller the particle 
size the more rapidly dehydration occurs, which is justified on the basis of surface area and/or 
the existence of crystal defects. Crystal defects can be encountered when the hydrate is 
subjected to high-energy particle size reduction, and can have consequent effects on storage 
and dosing. 
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1.2.1 Structural Classification of Hydrates3 
1.2.1.1 Isolated lattice sites 
This type of hydrate represents structures with water molecules isolated from direct contact 
with other water molecules by drug molecules. ln cephradine dihydrate, for instance, no line can be 
drawn between separate water pairs without passing through a portion of cephradine molecule. The 
two water molecules adjacent to the cephradine molecule were found to be easily lost because 
presumably no hydrogen bonds network exists between water molecules. Correspondingly, the DSC 
thermogram showed two incompletely resolved, but sharp, endotherms at approximately 1 00°C. The 
TGA thermogram also showed a sharp weight loss. 
1.2.1.2 Lattice Channels 
Water in this class of hydrates occupies lattice channels, i.e. water molecules lie next to each 
other along a single direction forming channels (e.g. ampicillin trihydrate). Lattice hydrates often 
show different thermograms to those of isolated lattice site network. The DSC and TGA thermograms 
for ampicillin trihydrate for example show that the dehydration onset occurs earlier and the water loss 
is found to be continuous up to l25°C. The latter observations were attributed to the fact that 
dehydration begins at one end of the crystal and carries on through the channels towards the other 
end. 
Lattice channel hydrates can be subdivided into different sets3: 
(i) Expanded Channels (non-stoichiometric) 
Hydrates of this class can accommodate additional moisture in the channels when exposed to 
high humidity (e.g. chromylin sodium). 
(ii) Planar Hydrates (lattice planes) 
This subclass of hydrates has water localised inside a two-dimensional plane. Examples of 
this class are sodium ibuprofen and nedocromil zinc. 
1.2.1.3 Metal-ion Coordinated Water (Ion Associated Hydrates) 
Hydrates of this type have metal ion coordinated water. The metal-water interaction can be 
quite strong compared to other molecular interactions in crystals, hence dehydration takes place at 
very high temperatures. Drugs with solubility, dissolution or handling problems are mostly 
crystallised as Na\ K+, Ca+2 or Mg+2 salts and often hygroscopic. The tetra-decahydrate and tetra-
dihydrate of calteridol calcium are examples of this type of hydrates. Calteridol calcium is used as a 
chelating excipient in a parenteral formulation which has a metal cation and contains water in 
channels. ln the tetra-decahydrate there are four water molecules associated with each central calcium 
and ten lattice water molecules associated with channels perpendicular to the ac plane. 
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1.3 Amorphous Forms 
Amorphous materials are generally more energetic than crystalline materials; hence they tend 
to have higher solubilities and rates of dissolution, which makes amorphous forms important in 
pharmaceutical industry. Amorphous phannaceutical materials are usually obtained by crystallisation 
procedures far from equilibrium such as rapid solidification from the melt, lyophilisation or spray 
drying, removal of solvent from a solvate, precipitation by changing pH or by mechanical processing 
like granulation, grinding or milling. 
1.4 Literature Sources of Polymorphic and Solvated Forms2 
There are a number of sources and databases for consultation on organic polymorphs and 
solvates. The Cambridge Structural Database (CSD) is one of the most important and it is 
continuously updated. The database includes crystal structures of organic and organometallic 
compounds along with their bibliographic information. The Crystallographic Information File (CIF) 
for each structure can be extracted from the database which contains the available crystallographic 
information on each compound or polymorph (unit cell parameters, space group, atomic positions, 
instrumental settings, etc ... ). A second crystallographic data base is the Powder Diffraction File 
(PDF) which consists of organic, organometallic and inorganic compounds. A third source is the 
patent literature, where enormous numbers of patent issues involve pharmaceutical polymorphs, 
crystalline forms and even amorphous forms. 
1.5 Importance of Pharmaceutical Solid Forms 
Pharmaceutical solid forms (polymorphs and solvates) are vital in industry as different forms 
exhibit different physical properties which influence their performance in formulation. Many 
pharmaceutical materials (active drug substances and excipients) are found to be polymorphic. 
Examples of such excipients are lactose, glucose, sucrose, magnesium stearate, calcium phosphates, 
and mannitol. Enormous numbers of examples of polymorphs and solvates for active ingredients are 
present in the literature1•2A'5. The nature of solid excipients has an impact on the final physical 
properties of the formulation (e.g. tablets) or may induce a polymorphic conversion of the active 
ingredient. Pharmaceutical materials have been shown to have variable properties between different 
crystal modifications. The physical properties of each solid form are important for evaluation of the 
relative stability, efficacy and dissolution rates, which in turn are related to bioavailability. 
Increasing attention is being paid by regulatory agencies to the preparation, identity, 
characterisation, purity, and properties of the crystal forms used in pharmaceutical products. Such 
information is now required by the US Food and Drug Administration (FDA) in a New Drug 
Application (NDA). The International Conference on Harmonisation (ICH) has also guidelines 
(Q6A) 6 on this issue. 
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1.6 Enantiotropic and Monotropic Poiymorphs in The 
Pharmaceutical Industry 
One of the key questions regarding polymorphic/ solvated systems is the relative stability of 
various crystal modifications and the changes in the thermodynamics accompanying a phase 
transformation. Polymorphs can be classified as one of two types; enantiotropic and monotropic. The 
latter is defined as a polymorphic system containing two forms in which one undergoes an irreversible 
phase change to the second form. The former type represents polymorphic systems of two forms in 
which the two phases can undergo a reversible transition. Increase in temperature for an enantiotropic 
system leads to the formation of a form at high temperatures which is metastable on cooling to 
ambient temperatures. Such forms can often exist for long periods of time before transforming to the 
stable form. Metastable forms are higher in energy and metastable with respect to the most stable 
forms below the transition temperature. Metastable and unstable forms typically have greater 
solubility than the more stable forms in a particular solvent and at a given temperature, i.e. stable 
forms are the least soluble. Consequently, metastable forms are of high importance in pharmaceutical 
industry and advantageous to selectively obtain and maintain in the formulation. Attempts are carried 
out to inhibit the growth of the stable form in order to favour the growth of a metastable form2•7• A 
pharmaceutical metastable solid form can relax to the more stable form during processing. Examples 
of pharmaceutical metastable forms which relax to a more stable form are commonly found in 
suspensions, in solid dosage forms, and of course via dissolution. Solid-state relaxation is more likely 
to be a slow process but is possible during storage. Accelerated stability studies may exceed the 
temperature of a polymorphic phase transition or dehydration, causing transformation of metastable 
forms to be rapid because of molecular mobility increase. Hydration of a drug can be induced by high 
humidity. Additionally, exceeding the glass temperature of an amorphous form can induce 
crystallisation and/or other mobility-related problems3. 
1. 7 Hydrogen Bonding in. Solid Forms 
Hydrogen bonds are amongst the most important intermolecular interactions found in solids, 
and hence are the subject of several structural studies. Additionally, hydrogen bonds affect the 
stability and colligative properties (e.g. melting point) of a solid form. Hydrogen bonds are normally 
found in solid forms where potential hydrogen bond donors and hydrogen bond acceptors are 
available. Hydrogen bonding between drug molecules and water is very common in hydrates where 
water acts as a hydrogen bond donor and acceptor at the same time. A water molecule can form up to 
four hydrogen bonds; two from the two hydrogens (donor) and another two from the two lone pairs on 
the oxygen (acceptor). Knowing how water is occupying the crystal structure as well as information 
on hydrogen bonds is very important for hydrates (see hydrates section). 
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the oxygen (acceptor). Knowing how water is occupying the crystal structure as well as information 
on hydrogen bonds is very important for hydrates (see hydrates section). 
1.8 Controlling the Preparation of Sonid Forms; Disappearing 
Polymorphs 
The basic experimental conditions that must be defined for targeting a certain solid form 
comprise the solvents, temperature range, rate for evaporation or cooling and many others. These 
conditions are called the occurrence domain. Control over the process of polymorph preparation is not 
easy to achieve. Moreover, there are crystal forms that are observed over a period of time but are 
apparently replaced by a more stable crystalline form in later preparations. This phenomenon is called 
"disappearing polymorphs"8. A classical example of this phenomenon in a pharmaceutical system is 
ritonavir9·10. There is a variety of conditions (mentioned above) controlling the reproducibility of 
crystallisation which makes identifying the factor responsible for this phenomenon a very hard task. 
1.9 Analytical Techniques 
Many analytical techniques have been used for the characterisation of solid forms. The 
definitive evidence for the identity of solid forms is provided by the crystal structure (obtained from 
X-ray or neutron diffraction) 11 •12 • Other analytical techniques can be applied for routine analysis of 
solid forms. Most commonly used in the pharmaceutical industry are powder X-ray diffraction 
(XRPD) and thermal analysis (TGA, DSC and hot-stage microscopy). FT -IR, Raman and near-IR 
spectroscopy are used to a lesser extent. However, many researches have been carried out, in the past 
decade or so, using solid-state NMR (especially using 13C cross polarization magic-angle spinning; 
13C CPMAS 1). The huge development in the techniques relating to CPMAS NMR and the increase of 
the requirements of the regularity and patent authorities were the reason behind the increasing 
importance of solid-state NMR. In some cases, solid-state NMR has accurately identified different 
solid forms while X-ray methods falsely indicated only a single structure13 • Molecular level mobility 
information has also been deduced from relaxation time measurementsl. 14• 
In practice, characterisation of polymorphs/ solvates should involve as many techniques as 
possible; the more information available from the analyses, the greater the understanding and possible 
control over the solid forms. For instance, single-crystal XRD analysis gives a definitive crystal 
structure of a certain form but it cannot generate information about the purity of the whole powder 
(very important in industry). XRPD assists phase identification as well as purity information 
(qualitative and quantitative), though it has been reported that it is hard to generate information at a 
molecular level. Moreover, there are many cases reported where XRPD for isomorphous solvates was 
unable to distinguish between them (e.g. neotame 13 , aspartame 15 , erythromycin 16, •.. etc). For 
molecular information, solid-state NMR plays a leading role. Additionally, solid-state NMR can 
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readily identify and quantify purity of different solid forms including amorphous materials. 
Information on solid mobility has been also obtained. However, other analytical techniques including 
thermal analysis and microscopy are normally important for quick complementary analysis, providing 
information on heat capacity, phase transitions and relative stability. 
L10Steroids 
Steroids are of considerable pharmaceutical importance and are of particular interest in the 
research reported. Hence, Polymorphs and solvates (including hydrates) are relatively common among 
steroids. Much research has been carried on steroids utilizing solid-state NMR17-19• Moreover, steroids 
are know to have stable hydrates and hemihydrates20"21 • They generally crystallise well and give high-
quality CPMAS spectra22-27 . 
1.11 Thesis Overview 
It was aimed in the reported research to study the structural properties of various solid 
modifications of two steroids (androsterone and finasteride) and to gain understanding of the 
relationship between the NMR chemical shifts of these forms and crystallography. To this end the 
study utilised XRD (powder, together with single-crystal where appropriate) and NMR (with magic-
angle spinning methods for the solids, backed up by solution-state techniques where relevant). 
Thermal analysis (TGA and DSC) methods were also consulted where appropriate. In order for the 
investigation to proceed, it was decided to attempt to implement several preparation procedures to 
obtain samples of finasteride solvates, some of which are novel. The intention was to show that 
magic-angle spinning NMR can be used to detect the "solvent" molecules (and thus to readily 
characterise them) and to ascertain to what extent the stoichiometry of the solvates can be established. 
- 6 -
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2.1 Nuclear Magnetic Resonance (NMR) 
2.1.1 Solid-State NMR 
2.1.1.1 13C Cross Polarisation and Magic Angle Spinning NMR (13C CPMAS 
NMR) 
The Cross Polarization (CP) pulse sequence (Figure 2.1) is normally used to enhance 
the signal-to-noise ratio for spectra and to obtain shorter recycle times by transferring 
magnetisation from naturally abundant nuclei (normally 1H) to dilute nuclei (e.g. 13C and 
tsN).t-3 
The 13C CPMAS NMR spectrum of androsterone hemihydrate was measured at 
ambient temperature using a V ARIAN Inova spectrometer, which operates at 75.40 MHz for 
13C and 299.18 MHz for 1H. All other spectra were measured at ambient probe temperature 
using a Varian InfinityPlus spectrometer, which operates at 125.65 MHz for 13C and 499.70 
MHz for 1H. Samples were packed, with light grinding, into 5.0 mm o.d. rotors (except for the 
acetic acid solvate, for which a 2.5 mm rotor was used). 
For finasteride samples, the contact times were in the range 1-5 ms, with spin rates 
8.5 kHz, recycle delays of 4 s and acquisition times of 40 ms. The duration of the proton 90° 
pulse was 4.4 JlS. Proton decoupling was carried out with the TPPM4 method (except for the 
acetic acid solvate, for which SPINAL5 was used). The proton decoupling power was 
equivalent to 55-63 kHz for all spectra except for the acetic acid solvate, for which 100 kHz 
was applied. Good quality spectra could be obtained with accumulation of 150-220 transients 
for the 5 mm probe, though 10000 transients were used for the 2.5 mm probe (acetic acid 
solvate). 
For androsterone samples, the contact times were in the range 1 ms, with spin rates of 
5 and 9 kHz (for the hemihydrate and form 1, respectively), recycle delays of 60 s and 
acquisition times of 40 and 75 ms (for form 1 and the hemihydrate, respectively). The 
duration of the proton 90° pulse was 4.3 JlS. Proton decoupling was carried out with TPPM4 
using proton decoupling power equivalent of about 60 kHz. The hemihydrate form spectrum 
was acquired over 240 transients and for form 1; 900 transients were recorded. 
The 13C chemical shifts were indirectly calibrated through the high-frequency adamantane 
carbon signal (at 38.4 ppm relative to TMS). 
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pwgoo 
contact time 
1 H channel decoupling 
-
X y y 
13c channel 
Figure 2.1. CP pulse sequence. 
2.1.1.2 13C Direct Polarisation 
Direct polarisation (i.e. simple pulse-and-acquire) was carried out on some finasteride 
samples (ethyl acetate and THF solvates) in order to distinguish the mobile 13C peaks due to 
the solvent molecules, which can appear in the spectrum without having to have cross 
polarisation. The duration of the 90° pulse was 4.4 f.LS with a recycle delay of 11.0 s and 27 
transients. 
2.1.1.3 Dipolar Dephasing2 
A Dipolar Dephasing pulse sequence (Figure 2.2) is normally performed to 
distinguish the quaternary and methyl carbons in a 13C spectrum, hence aiding assignment of 
the spectrum. The pulse sequence is similar to a CP sequence but adding a window of time 't 
during which the carbons are allowed to relax before acquisition. The time is set to be 
sufficient for the signals from CH and CH2 carbons to dephase, hence observing only methyl 
and quaternary carbons. The dipolar dephasing delay time (•) was 40.0 11s. 
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dephasing 
delay 
1/spin-rate 1/spin-rate 
Figure 2.2. Dipolar Dephasing pulse sequence. 
2.1.1.4 Selective Population Inversion6 
This pulse sequence also simplifies the 13C spectrum so that the CH2 and CH peaks 
are distinguished. A phase inversion is applied to the CP sequence so that the inversion time 't 
is chosen to be appropriate for the inversion of the CH2 carbons (Figure 2.3). Since the CH2 
peaks dephase faster, other carbon types will still appear in the spectrum though their 
intensities will decrease while the former will show up as base line or negative peaks. Very 
long inversion times will null or invert the CH peaks but the CH2 peaks are inverted faster 
(approximately twice as fast). Typical inversion times were 25 and 50 IJ.S for CH2 and CH 
carbons respectively. 
pwgoo 
1H channel decoupling 
X y -y y 
13C channel 
T 
Figure 2.3. Selective Population Inversion pulse sequence 
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2.1.1.5 1H MAS NMR 
Proton MAS spectra were obtained on a Varian InfinityPlus spectrometer, which 
operates at 499.70 MHz for 1H using 5.0 or 2.5 mm rotors, spinning at 8.5 and 20.0 kHz 
respectively. Pulse angles of 90° were used, with recycle delays of 1 s and 5 s and numbers of 
transients of 4 and 10-20 for the two probes respectively. The 1H chemical shifts were 
indirectly calibrated through the adamantane proton signal at 1.9 ppm (unresolved peak) 
relative to TMS. Empty rotor background was not recorded. 
2.1.1.6 Saturation Recovery 
Proton spin-lattice relaxation times (T1) were obtained for various forms of 
finasteride by the saturation-recovery method at ambient temperature using the 5 mm probe 
under 1H MAS conditions. Saturation was obtained by 100 90° pulses separated by 10Jls. Plots 
were derived using between 10 to 20 points, with 1 s recycle delays. The saturation recovery 
data were fitted using the following equation: 
Equation 1 
where I('r) is the intensity at the recovery time • and 10 is the maximum intensity at F oo. 
Figure 2.4. Saturation recovery pulse sequence 
2.1.1.7 Variable Temperature NMR 
A variable-temperature 13C NMR experiment on finasteride dioxane solvate hydrate 
was carried out. The spectra were obtained at ten degree intervals from 50°C to 11 ooc and 
then at ll5°C and l25°C, with ea. 45 minutes spent at each temperature. For each temperature 
set, the probe was left for 15 minutes for heat equilibrium and the total time to record each 13C 
spectrum was 10 minutes. Saturation-recovery experiments were performed at each 
temperature to determine T 1 proton relaxation times under spinning and static conditions. A 
13C spectrum was checked towards the end at ambient temperature. 
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2.1.2 Solution-State NMR 
2.1.2.1 1D NMR 
A Varian lnova spectrometer was employed for solution-state NMR spectra of 13C at 
125.68 MHz. The spectra were obtained wi th recycle delays of 3 s, acquisition time of 1.4 s, 
pulse angles of 45° and 3000 and 5000 transients (for finasteride and androsterone, 
respectively). Proton decoupling for 13C spectra was achieved by the WALTZ-16 pulse 
sequence. 
The 1H spectra were obtained wi th a Yarian lnova spectrometer at 499.77 MHz .The 
parameters were as fo llows: 30 s recyc le delays, 4.1 s acquisition times, 45° pulse angle and 
32 transients. 
2.1.2.2 Heteronuclear Single Quantum Correlation (HSQC)7 
The 2D experiment shows one-bond correlation between dilute nuclei ( 13C or 15N) 
and protons. Hence, carbon or nitrogen atoms not attached (single bond) to any hydrogen 
atoms do not show any correlation. The pulse sequence is illustrated in Figure 2.5. 
!Vyvvvv .. 
' 
------ t1 ___ __,... 
Figure 2.5. The pulse sequence of HSQC. The black rectangle represents a 90° pulse, the white 
rectangle represents a 180° pulse and the grey rectangle represents broadband decoupling. 
2.1.2.3 Heteronuclear Multiple Bond Coherence (HMBC) 7 
HMBC is a long-range correlation experiment (Figure 2.6). Correlation between the 
dilute nuclei, say 13C, and protons which are separated by 2-3 bonds are observed. 
IH I~ 't .. ~ -- t2---. lAAAAAA ... 
I I 
yvvvv~v· 
t1 ~I ne 
~ Tl~ 
Figure 2.6. The pulse seq uence of HMBC. The black rectangle represents a 90° pulse and the 
white rectangle represents a 180° pulse. 
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2.1.2.4 Nuclear Overhauser Effect SpectroscopY (NOESY)7 
The NOE effect is shown between nuclei which exhibit cross relaxation. In order for 
the cross relaxation to happen, the nuclei have to be close in space. Hence, this experiment is 
different from the previous 20 NMR experiments where the correlations in this experiment 
are between nuclei which are correlated through space (not through bonds as in HMBC). See 
Figure 2.7 for illustration of the pulse sequence. 
Figure 2.7. The pulse sequence ofNOESY. The black rectangle represents a 90° pulse. 
2.2 X-ray Diffraction. 
2.2.1 X-ray Powder Diffraction (XRPD) 
Two diffractometers (Siemens 05000 and Bruker 08 Advance) were used for all 
routine work. They utilised CuKau radiation. All sample scans were in the range of 5-70 or 
5-50° 2fJ, with a 20 mm variable-divergence slit and a time step of 1 s. Samples with large 
crystallites were ground under liquid nitrogen before examination in order to minimise 
preferred orientation effects. Samples were run on silicon slides except for androsterone form 
1, which was run on a glass slide. The transformation of androsterone hemihydrate to form1 
was monitored on the Bruker 08 Advance over 24 hours. The sample was examined on a 
silicon slide with 28 range of 5-50, 10 mm variable-divergence slit and a time step of 0.3 s 
(each scan took -14.7 minutes). 
2.2.1.1 Rietveld Fitting8 
The Rietveld method is reported as one of the fastest and most accurate quantitative 
phase analysis methods used in XRPO, especially because of the possibility to introduce a 
preferred orientation correction in addition to quantitative analysis with respect to all present 
phases. To carry out the quantitation, the atomic positions of each phase are needed1 along 
with structural data. Scale factors for every phase present in the mixture are proportional to 
the fraction of the unit cells present in the irradiated volume of the sample. Hence, the scale 
factors can be converted into weight, molar or volume fractions. 
1 The CIF files were used in all fittings for this purpose, which were taken form the CSD. 
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The Rietveld9 method is a crystal structure refinement method which refines the 
structural and instrumental parameters of a model to fit with the experimental pattern. The 
refinement is carried out by non-linear least square minimisation with the minimised 
function, <1>: 
11 
<I> = LW 
1 
(Yobs _ ycalc )2 Equation 2 
i=l 
where n is the total number of points measured in the experimental pattern, W; is the weight 
assigned to the i1h data point which often equals (1/ yobs), yobs is the observed intensity at 
point i and ycatc the calculated intensity at point i. 
The quality of the fitting is usually indicated by computing profile residual (Rp), 
weighted profile residual (Rwp), expected residual (Rexp) and goodness of the fit (X2); see the 
following equations. 
IIY/bs -Y/alc I 
R = i=t xlOO% 
p 11 
Lyiobs 
i=l 
n 
LW 
1 
(Yobs _ ycaic )2 
R i=l wp= ~--~~-----------
LW; (Y;obs )' 
i=l 
!12 
1/2 
xlOO% 
n -p 
xlOO% 
n 
LW; (Y;obs)' 
i=l 
11 
LW 
1 
(Yobs _ ycalc )2 
X2 = i=t =[R"'P ]
2 
n- p Rexp 
where pis the number of free least squares parameters. 
Equation 3 
Equation 4 
Equation 5 
Equation 6 
However, none of these parameters replace the importance of observing the 
difference plot between the observed and calculated patterns, which is shown at the bottom 
(grey colour) of each Rietveld fit. For the majority of the work reported here (where effects 
such as preferred orientation are often severe) we present graphical plots rather than 
quantitative agreement indices. 
The plots of Rietveld fits used throughout the research show the percentage of the phase( s) in 
the solid examined at the right top, the data file name at the left top, the observed pattern in 
blue and the calculated pattern in red. 
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The parameters refined are: instrumental parameters, zero point, background, scale 
factor, unit cell parameters, temperature factors, peak shape and preferred orientation by 
spherical harmonic function. In the refinements which were carried out using finasteride ethyl 
acetate solvate model, the disordered atoms of the solvent (ethyl acetate) were excluded. 
2.2.2 Single-crystal X-ray Diffraction (single-crystal XRD) 
All single-crystal XRD data collections were performed on a Bruker SMART 6000 
diffractometer, equipped with a CCD detector, Mo Ka source and an Oxford Cryosystems N2 
cooling system. In each case, a full sphere of data was collected and a multiscan absorption 
correction 10 was applied to the raw data. Frames were integrated using the program SAINT 11 • 
The crystal structure was solved by direct methods using the SIR92 software12 and refined 
using the Oxford Crystals suite13 • The positions and anisotropic atomic displacement 
parameters of all non-hydrogen atoms were refined. The same shifts in fractional coordinates 
obtained for hydrogen carrying C and N atoms were applied to the hydrogen atoms 
themselves (riding model) i.e. positions of hydrogen atoms were not refined independently. 
All crystallographic information, including experimental and structural details and the 
agreement factors obtained in the refinements, is given in Table 9 of chapter 2. All data 
collections and refinements were done by Or I.R. Evans at the single crystal XRD service2. 
2.3 Thermal Analysis 
2.3.1 Differential Scanning Calorimetry (DSC) 
Thermal events in DSC appear as deviations from the baseline, in either an 
endothermic or exothermic direction, depending upon whether more or less energy has to be 
supplied to the sample relative to the reference material. The direction of the exothermic event 
is shown on the DSC thermogram (exo down). The thermal events shown in the thermogram 
represent phase transformations. The intercept between the tangent of the melting peak onset 
and the baseline provides the melting point. The difference in the enthalpy for each DSC 
event is shown in the plot14. 
The DSC analysis was carried out on a TA Instruments system. All samples were run 
from 25°C to 300 oc. Nitrogen was used as purge gas. The heating rate was kept constant at 
I oc min-1. Aluminium sample pans were used for all samples. A single point calibration was 
carried out using indium (melting point 156.60°C) as a standard sample. 
2 Chemistry Department, Durham University. 
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2.3.2 Thermal Gravimetric Analysis (TGA) 
TGA is carried out to quantify the mass loss from a sample while being heated, here 
revealing information about the solvent included in the solid forms. The difference in they-
scale before and after the loss step represents the percentage mass loss (shown in the 
thermogram as "Delta Y"). A Perkin-Elmer Pyris 1 instrument was used for all TGA samples. 
Nitrogen was used as the purge gas and the heating rate was kept constant at 2°C min-1• 
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Chapter 3: Literature Review on Finasteride Solid 
Forms 
3.1 Introduction 
Finasteride (N-t-butyl-3-oxo-4-aza-Sa-androst-1-ene-17{3-carboxamide) is an 
azasteroid which is considered as the most potent Sa-reductase inhibitor1• A number of 
finasteride solid forms are reported; five (supposedly-different) polymorphs and three solvates 
are mentioned in the literature. Two of the polymorphs (form I and TI) have been described in 
the patent literature2•6 and also in the scientific literature7•9• The other three were only reported 
in the patent literature: novel form Ill claimed by Reddy et a/.5'6 in 2005 and another two 
forms (H1 and H2) claimed in the patent by Parthasaradhi et a/.10 in 2004. Two of the 
solvates were reported first in the scientific literature, with crystal structures, by Wawrzycka 
et al. 9 and later on they were reported in the patent literature5•6 but prepared by different 
methods and characterised by XRPD. The solvates are an acetic acid solvate and an ethyl 
acetate solvate. A third solvate obtained from dioxane was characterized by Morzycki et al. 7 
using FT-IR and solid-state NMR but the crystal structure was not confmned. 
H3C ~5 CH ~/24 3 
O 22-CH3 
H C 0.. I 23 
3 18 '\:2o-N, 
t f H 
/ 12 , 17 
11 .......... 13- \ 
H399 I c I 0 16 
1 ' 9 14 I 2-::/ '-.... 10 ,...... '-...a/.: - 15 
I A I B I t=i 
3 5 7 0~ "-N/~'-....6/ H H 
Molecular structure of finasteride 
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3.2 Finasteride Polymorphs Reported in The Scientific and 
Patent Literature 
3.2.1 Form I 
Finasteride form I was reported in both the scientific7-9 and patent2-6 literatures. The 
crystal structure of finasteride form I was reported by Wawrzycka et al. 9 and Wenslow et al. 8 
with Cambridge Structural database (CSD) codes of WOLXOKOl and WOLXOK02, see 
Table 3.1. Finasteride form I crystallizes in the orthorhombic space group P212121 (see Table 
3.1 for unit cell parameters and Figure 3.1 for a view of the crystal structure). 
Form I has strong intermolecular hydrogen bonds between ring A lactam groups 
where the lactam NH group is the donor and the carbonyl from another molecule is the 
acceptor. In the opposite part of the molecules C-H ... O hydrogen bonds were observed 
between neighbouring methyl and peptide groups9. The lactam-to-lactam hydrogen bonding 
was reported to be strong, with the distance from the lactam nitrogen of one molecule to the 
lactam oxygen of its partner being 2.85 A. The lactam-to-lactam chains produced are parallel 
to the crystallographic a axis. The tert-butylamide site of the molecule was found to be 
uninvolved in hydrogen bonding due to the steric effect of the tert-butyl group. This was 
confirmed from interatomic distances measured by XRD. It was also proved by IR 
spectroscopy where the NH stretch frequency in form I was similar to that of the solution state 
(in chloroform) frequency, indicating that it is behaving closely to the solution state in 
solvents where hydrogen bonding is not present8• 
Form I undergoes a solid-to-solid transformation to form II on heating, which then 
melts on further heating. This solid-solid phase transition temperature was found to be 
dependent on the heating rate ( ~ 230 to 200 ° C as the heating rate is changed from 1 0 to 0.1 ° C 
I min). The melting temperature (257 OC) varies by only two degrees over the same range of 
heating rates [6]. The system was characterised by McCauley et a/. 4 to have a minor 
endotherm with a peak temperature of about 232°C, an extrapolated onset temperature of 
about 223°C with an associated heat of about 11 J/g and by a major melting endotherm with a 
peak temperature of about of 261 °C, an extrapolated onset temperature of about 258T and an 
associated heat of about 89 J/g. 
Form I was characterised by 13C CPMAS NMR and the chemical shifts were 
assigned7·8. The assignments were consistent with the crystallographic information provided 
byXRD. 
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T bl 3 I C a e .. ll h' d rysta ograp IC fi 'd I'd f h r ata on masten e so 1 orms m t e Iterature. 
Form I Form 11 Acetic acid solvate9 Ethyl acetate solvate9 
Formula C23H36N202 C23H36N202 finasteride. 2finasteride. CH3COOH H20.C4H 80 2 
FW 372.556 372.556 432.59 851 .20 
Lattice 
orthorhombic monoclinic Monoclinic orthorhombic 
symmetry 
Space P212121 group P21 P2 1 P2 12121 
a (A) 6.437(1) 16.387(2) 12.170(1) 8.173(3) 
b (A) 12.712( I) 7.958(2) 8.16521(7) 18.364(6) 
c (A) 25.929(1) 18.115(5) 13.577(1) 35.65(2) 
an 90 90 90 90 
{JC) 90 107.25(2) 111.630(1) 90 
yC) 90 90 90 90 
z 4 4 2 4 
Z' I 2 I 2 
Unit cell 2121.7(6) 2256(2) 1254.1 (2) 5350(4) 
volume (A3) 
CSD code WOLXOK02, WOLXOK03 , WOLXEA WOLXIE WOLXOKOl WOLXOK 
Melting 253-256 253-256 255-257 252-255 point ("C) 
Figure 3.1. Form I crystal structure and packing inside the unit cell, viewed along the a 
crystallographic axis. Dotted lines represent hydrogen bonding. 
- 21 -
Chapter 3: Literature Review on Finasteride Solid Forms 
3.2.1.1 Reported Methods of Preparation 
The Following methods have been reported for the preparation of form I. Given the 
existence of solvates, some of these methods may be questionable particularly where the 
characterisation was very limited. 
(i) Dissolving finasteride in glacial acetic acid (ea. 100 mg/mL) and adding water with 
stirring until the weight % of water equals or exceeds 84%. The resulting solid phase 
is collected by filtration and dried under vacuum and at about 50°C4 • 
(i) Heating polymorphic form 11 of finasteride to about 25°C in water or an organic and 
recovering the resultant solid phase, e.g. by filtration. Additionally it was prepared by 
stirring form II overnight in dry toluene at ambient temperature, and recovering the 
resultant solid phase. Form I was also obtained by stirring form 11 overnight in dry 
acetonitrile at ambient temperature, and recovering the resultant solid phase4. 
(ii) Crystallisation from an ethanol I water (1: 1 0) solution9• 
(iii) Crystallisation directly from dry ethyl or isopropyl acetate4'8. For example, to produce 
form I of finasteride from an ethyl acetate/ water mixture, the amount of water used 
is at most about 3.5 mg/mL, and from an isopropyl acetate/ water mixture, the 
amount of water used is at most about 1.6 mg/ mL, both at an ambient temperature of 
about 25°C. The isolated solids are dried under vacuum at about 50° C. 
(iv) Recrystallisation from a binary solvent mixture (acetic acid and water). The exact 
concentration was not reported7. 
(v) Dissolving finasteride in a solvent, distilling off the solvent from the solution then 
adding a non-solvent and finally isolating the solid. The solvent can be methanol or 
dichloromethane and the non-solvent can be water, hexane, heptane, toluene, xylene, 
isobutyl acetate or isopropyl acetate3. 
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3.2.2 Form 11 
Form 11 is a monoclinic metastable form of finasteride, which is formed at higher 
temperatures (above 175 °C). Unit cell parameters of low reliability were determined by 
Wawrzycka et a/. 9, the crystals having been prepared as illustrated in point (iv) under methods 
of preparation section 2.1.09• Following that, the crystal structure was determined by 
Wenslow et a/. 8• Form 11 crystals have a P2 1 space group with two drug molecules in the 
asymmetric unit (see Table 3.1 for unit cell parameters). The conformations of the two 
molecules in the asymmetric unit were found to be similar. It was also reported that "the 
similarity in confirmation of the three molecules (one in form I and two in form 11) suggests 
that the polymorphism between the forms is lattice rather than conformational"8. It was shown 
that strong hydrogen bonding due to the lactam group is present, which is in agreement with 
the case of form I where the measured hydrogen-bond distances from nitrogen to oxygen were 
2.85 A in form I and 2.85 and 2.80 A for the two molecules in form II. The lactam-to-lactam 
chains caused by this hydrogen bonding are parallel to the crystallographic axis b. Also, as in 
the case ofform I, the tert-butylamide substituents of the 5-membered ring are not involved in 
any hydrogen-bonding in the lattice; as the nearest contacts between the amide nitrogen, in 
any of the three molecules, and an acceptor atom were larger than 4.2 A. 
The lactam-to-lactam hydrogen-bonding interaction in form 11 was also proved by IR 
spectroscopy. The spectrum showed a broad and strong NH stretch at 3213 cm·1, and the 
lactam carbonyl stretch at 1655 cm·1• The tert-butylamide side chain NH stretch at 3440 cm-1 
was found to be sharp, and its high frequency indicates that it does not participate in a 
hydrogen bond. The 13C CPMAS spectrum of form 11 was reported and assigned The 
assignments were consistent with the crystallographic information provided by XRD8• 
Form 11 was also characterized by DSC at a heating rate of 20°C/ min and in a closed 
cup, exhibiting a single melting endotherm with a peak temperature of about 261 OC and 
extrapolated onset temperature of about 258°C, with an associated heat of about 89 J/ g4• 
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3.2.2.1 Reported methods of Preparation 
The Following methods have been reported for the preparation of form 11: 
(i) Dissolving finasteride in glacial acetic acid (ea. 100 mg/mL) and adding water with 
stirring until the weight % of water equals about 75-80%. The resulting solid phase is 
collected by filtration and dried under vacuum at about 100 T 4• 
(ii) Heating form I up to about 150 "C, holding for a time sufficient to convert form I to 
form 11, for example for about an hour, and cooling back to room temperature4• 
(iii) Recrystallisation from ethyl acetate containing from about 3.5 to 30 mg/mL of water, 
or from isopropyl acetate containing from about 1.6 to 15 mg/mL of water, at ambient 
temperature (about 25 "C); i.e. the amount of water used in the solvent mixture will 
be more than that used to produce form I from the same organic solvent. The isolated 
solids are dried under vacuum at about 80° C4• 
(iv) Obtained both by thermal decomposition of the acetic acid solvate (175 oc 30 min) 
and by sublimation of form I, acetic acid solvate or the ethyl acetate solvate (about 
235 oc 30 min), using hot stage microscopy. In this case unit cell parameters of poor 
quality crystals were determined9• 
(v) A molten sample of the drug was held at 249 oc and seeded with a tiny crystal of the 
form 11 polymorph. Over a period of several hours, the sample was crystallized in the 
melting- point capillary8• 
(vi) Recrystallisation from a binary solvent mixture (acetic acid and water). The exact 
concentration was not reported 7• 
'• 
··-..... 
Figure 3.2. Form 11 crystal structure inside the unit cell with the view along the a 
crystallographic axis. Dotted lines represent hydrogen bonding. 
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3.3 Finasteride Polymorp.bs Reported in The Patent 
Literature 
3.3.1 Form 1115'6 
Form Ill was isolated by Reddy et al. 5"6 while doing process development to optimize 
the yield and quality. The crystal structure was not determined for this form but it was 
characterised by DSC, FT-IR and powder XRD as follows: 
(i) DSC melting endotherm with peak temperature of about 262·c proceeded by another 
minor endotherm at about 245•c and an exotherm at about 253·c (Figure 3.3). 
(ii) The XRPD pattern and 28 values were reported; see Figure 3.3 and Table 3.2, 
respectively. 
(iii) Characteristic FT -IR wave numbers were reported as the following: 3427, 3233, 
2931, 1679, 1600, 1501, 1451 and 820 cm·'. 
263.27C 
0.00 l-------:;246;;.28~C 
262.65C 
·10.00 _,__......_....._.__.._.__._...._ ____ ......, 
100.00 200.00 300.00 
Tamp.(C) 
Figure 3.3. DSC thermogram data of the claimed form 1115•6 
80011 
6000 
2000 
0 ~~--~~~~~~~~~~~~~~==~==~c= 
20.000 30.000 40.000 
Figure 3.4. XRPD pattern for the claimed from 1115'6 
Table 3.2. The 20 values for the patented finasteride polymorphs. 
Form 20 values 
Form Ill 5.32, 10.70, 13.64, 14.96, 15.86, 16.12, 16.56, 17.20, 18.22, 19.60, 23.04 
Form H1 5.3, 5. 8, 6.8, 7.3, 9.0, 9.4, 10.7, 13.9, 14.9, 15.9, 17.3, 18.2, 19.0, 20.1 
From H2 5. 4, 9.9, 12.1, 14.5, 15.2, 16.2, 19.3, 29.0. 
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3.3.1.1 Reported methods of Preparation 
Finasteride form Ill was reported to be prepared by the following general methods: 
A- From Crude Finasteride: 
(i) Dissolving crude finasteride m water-immiscible organic solvents such as 
halogenated (preferably "dichloromethane, chloroform" in the patent), aromatic 
hydrocarbon, "preferably toluene", or organic solvents from alkyl acetates, 
"preferably ethyl acetate". 
(ii) Saturation of the solution with less polar solvent "aliphatic hydrocarbons, either 
straight chain or branched, preferably hexane or heptane or petroleum ether". 
(iii) Concentrating the solution and isolating the form Ill by conventional methods. 
B- From Finasteride Forms {form I, form 11, ethyl acetate solvate and acetic solvate} 
(i) Dissolving any of the solid forms (form I, form 11, ethyl acetate solvate and acetic 
acid solvate) in water-immiscible organic solvents such as halogenated "preferably 
dichloromethane, chloroform", aromatic hydrocarbon "preferably toluene" or organic 
solvents from alkyl acetates "preferably ethyl acetate". 
(ii) Distilling 60-70% of the solvent. 
(iii) Saturating the remaining solution with less polar solvent "aliphatic hydrocarbons 
either straight chain or branched, preferably hexane or heptane or petroleum ether". 
(iv) Concentrating the solution and isolating the form III by conventional methods. 
The following are two specific examples ofform Ill preparation mentioned in the patent: 
3.3.1.2 Conversion of Crude Finasteride to Form HI 
(i) Crude Finasteride was dissolved in methylene chloride (3 mL) at 25-35°C. 
(ii) The methylene chloride was saturated with petroleum ether (20 mL) at 25-30°C under 
stirring. 
(iii) The separated solid, after removal of methylene chloride and petroleum ether under 
reduced pressure at 50-60°C, is isolated with petroleum ether (2 mL) at 10-15 °C. 
(iv) The resultant solid was dried at ambient temperature (yield: 0.8 g). 
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3.3.1.3 Conversion of Finasteride Solid Forms to Form HI 
(i) 1 g of any finasteride solid form (form I, form II, ethyl acetate solvate or acetic 
solvate) was dissolved in 3 mL methylene chloride or chloroform. 
(ii) 60-70 % of methylene chloride was distilled off at 40-45 OC; in the case of 
chloroform it was distilled off at 60-70 OC. 
(iii) The resultant solution was saturated with petroleum ether (1 0 mL) at 40-60 OC 
under stirring. 
(iv) The solution was concentrated at 60-65°C at atmospheric pressure 
(v) The resultant residual solid was kept under vacuum at 60-65T for about 30 
minutes. 
(vi) The solid obtained was isolated and dried in an oven at 70-90 OC for 8-12 hours, to 
yield form-III (yield: 0.8-0.9 g) 
3.3.2 Form Hl and H210 
Parthasaradhi et a/. 10 describe the preparation of two "novel crystalline" forms, H1 
and H2, characterized only by XRPD. Table 3.2 shows the reported 28 for each claimed 
form; see Figure 3.5 and Figure 3.6 for the corresponding XRPD patterns. The form H1 is 
obtained from alcohols (methanol, ethanol, IPA individually or from mixtures of these 
alcohols), whilst form H2 is prepared from a dioxane solution. It is worth mentioning here 
that a dioxane solvates has been reported by Morzycki et al. 7 though the XRPD of the solvate 
was not examined. Both forms, H1 and H2, are reported to be suitable for pharmaceutical 
formulation in the patent. 
3.3.2.1 Preparation of form Hl 
The general method for the preparation of this form is by mixing finasteride and an 
alcohol, maintaining at about 40°C-60°C for about 10 minutes to 1 hour, then cooling slowly 
to about 0-5°C, maintaining for about 1-3 hours at this temperature and filtering the solid. The 
alcohol is methanol or ethanol or isopropyl alcohol or mixtures. The author reported that this 
procedure can be repeated using form H2 instead offinasteride to give form H1 offinasteride. 
The following is a specific preparation example: 
(i) Finasteride (10 g) is dissolved in methanol (25 mL), heated to 55°C and maintained at 
this temperature for 15 minutes. The solution is slowly cooled to ooc in 3 hours and 
maintained at 0°C for 1.5 hours. The separated crystals are filtered at ooc to give 8.5 
g of form H1 offinasteride. 
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(ii) Finasteride (10 g) is dissolved in isopropyl alcohol (40 mL), heated to 55°C and 
maintained at this temperature for 15 minutes. The solution is slowly cooled to ooc in 
3 hours and maintained at ooc for 1.5 hours. The separated crystals are filtered at ooc 
to give 8.5 g offonn H1 offinasteride. 
3.3.2.2 Preparation of form H2 
The general method for the preparation of this fonn is by dissolving finasteride in 
dioxane, maintaining at about 70°C-80°C for about 10 minutes to 30 minutes, then cooling 
the solution slowly to about 20°C-25°C maintaining at about 20°C-25°C for about 2 hours to 
4 hours and filtering the solid separated. The author reported that this procedure can be 
repeated using form H1 instead of finasteride to give fonn H2 of finasteride. The following is 
a specific preparation example: 
Finasteride (1 0 g) is dissolved m dioxane (50 mL), heated the solution to 80°C and 
maintained at 80°C for 15 minutes. The solution is slowly cooled to 25°C, maintained for 3 
hours at 25°C and the solid separated is filtered to give 9 g of fonn H2 of finasteride . 
... 
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·--.... 
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Figure 3.5. XRPD pattern for the claimed Hl from 10• 
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Figure 3.6. XRPD pattern for the claimed H2 from 10• 
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3.4 Finasteride solvates 
Three solvates have been reported in the literature; only two of them have crystal 
structures established in the scientific literature9 (the acetic acid and the ethyl acetate solvates) 
but no solid-state NMR published. In contrast, the dioxane solvate, was characterised by 
NMR and FT-IR7 but neither crystal structure determined nor XRPD reported. The first two 
solvates were also reported in the patent literature5•6 to be prepared with different 
methodologies and were claimed to be in agreement with XRPD data in the scientific 
literature. 
3.4.1 Acetic acid solvate (Finasteride-Acetic Acid Complex9) 
Finasteride acetic acid crystallises in the monoclinic space group P21 containing two 
molecules in the unit cell; see Table 3.1 for the unit cell parameters. The lattice contains one 
molecule of acetic acid. It decomposes, losing acetic acid, and recrystallises in the range 170-
1740C (melting point. 255-257°Ct The complex was found to be with a 1:1 molar ratio. The 
methyl groups of the host and solvent molecules were found to be in a nearly parallel 
orientation. Molecules of eo-crystallizing acetic acid are parallel to the two-fold screw axis. 
The finasteride lactam fragment and the carboxyl group of acetic acid are responsible 
for strong inter-molecular hydrogen bond formation. As in the case of forms I and 11, 
hydrogen bonding from the tert-butylamide group is absent; the distance between the 
finasteride peptide group and the acetic acid carboxyl group was measured to be 3.447(6) A, 
which was suggested to be outside the range for such hydrogen bonding11. Additionally, two 
weak intramolecular hydrogen bonding interactions of C-H ... O (methyl... carbonyl) type 
were reported. One of them comes from the interaction of the C 19 methyl and the peptide 
group oxygen of finasteride, and the second one comes from the methyl and carboxyl group 
atoms of acetic acid. 
3.4.1.1 Methods of preparation 
The following methods of preparation were reported: 
(i) Dissolving finasteride in an aqueous acetic acid of the ratio 4:6 (acetic acid: water) 
such that the amount of acetic acid is 5-15 v/w of finasteride, heating the resultant 
mixture to 70-80°C then cooling to 10-20°C, filtering the resulting material and 
isolating by conventional methods5•6. 
(ii) Crystallising finasteride from an acetic acid/ water mixture (about 2:1) by slow 
evaporation of the solvent9• 
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.......... >-. )- ... 
······· ...• 
Figure 3.7. The acetic acid solvate crystal structure, with the view along the a crystallographic 
axis. Dotted lines represent hydrogen bonding. 
3.4.2 Ethyl acetate solvate (Bis-finasteride Monohydrate Ethyl 
Acetate Clathrate)9 
The unit cell of this solvate contains one molecule of ethyl acetate for two molecules 
of finasteride. It crystallises in the orthorhombic space group P2 12121 and contains four 
molecules in the unit cell; see Table 3.1 for the unit cell parameters. Two molecules of 
finasteride in the asymmetric unit form dimers. This alignment is stabilized by two N-H ... 0 
hydrogen bonds between the lactam groups of ring A (Figure 3.8), and the hydrogen-bonded 
water molecule was shown to be a bridging unit connecting three finasteride dimers. The 
water molecule is a double donor of H atoms to the lactam 0 atoms, and an acceptor from the 
N atom of the tert-butyl side of finasteride. Hence, this solvate is the only finasteride solid 
form in the literature which has the tert-butyl side of finasteride involved with hydrogen 
bonding. The double-layer arrangement of the complexed host molecules was found to be the 
reason behind the formation of channels along the crystal a axis (Figure 3.9). The ethyl 
acetate molecules were found to be disordered, filling the channel of the clathrate crystal9. 
The stoichiometric ratio is reported to be finasteride: water: ethyl acetate = 2: I : 1. The ratios 
were presumably concluded from the XRD analysis of the disordered solvent molecules, as 
the author did not present evidence from any other analytical technique. 
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3.4.2.1 Methods of preparation 
The following methods of preparation were reported: 
(i) preparing a slurry of finasteride in an ethyl acetate, THF and water mixture such 
that the ratio ethyl acetate: THF: water is 1:1 :-0.1 and the ratio of this solvent 
mixture used is 1-3 v/w of finasteride, heating the resultant slurry to a temperature 
of 50 to 60T, then cooling the slurry to -5 to 5 ·c, recovering the resultant solid by 
filtration and washing with a chilled mixture of ethyl acetate, THF and petroleum 
ether5'6. 
(ii) Evaporating a solution of finasteride in ethyl acetate (containing traces of water); in 
this case unstable crystals are formed9. 
Figure 3.8. Hydrogen bonding pattern in the ethyl acetate solvate shown by Wawrzycka et a/.9 
Figure 3.9. Crystal structure packing for the ethyl acetate solvate with the view along the a 
crystallographic axis. Atoms inside the clathrate channel represent the disordered ethyl acetate 
molecule. 
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3.4.3 Dioxane solvate 7 
This form was obtained by recrystallisation from dioxane. The presence of dioxane 
was confirmed by solid-state NMR. The dioxane signal appeared at 67 ppm in the 13C 
CPMAS NMR spectrum. The stoichiometry of finasteride: dioxane was found to be 1: 1 by 
integration of the peaks in the 1H-NMR spectrum of the sample dissolved in CDCl/. The 
ratio was mentioned without showing the 1H-NMR spectrum or actual values of integrals. As 
mentioned earlier, no X-ray examination of this solvate was carried out. However, the solvate 
was additionally characterised by FT-IR spectroscopy. The reported FT-IR frequency does 
not readily distinguish between forms I and 11 and the prepared dioxane solvate (Table 3.3). 
Table 3.3. Selected infrared frequencies for examined finasteride solid forms by Morzycki et a/.1• 
Infrared wavenumber (cm-1) 
Functional Form I Form I Dioxane solvate Group 
NH 3429 3439 3429 
NH 3241 3221 3240 
C=O 1689 1689 1689 
C=O 1669 1678 1668 
3.5 Experimental Overview 
The next chapter will be dealing with the preparation and characterisation of the solid 
forms (polymorphs and solvates) mentioned herein by XRPD, solid-state NMR and thermal 
analysis where applicable. Other newly prepared solvates will also be presented. 
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Chapter 4: Finasteride Solid Forms 
4.1 Finasteride Polymorphs Reported in the Scientific Literature 
In this section, characterisation of polymorphs reported in the scientific literature will be presented. 
4.1.1 Form I 
The sample was sent by Hikma Pharmaceuticals-Jordan (B#060 1 02) and manufactured by 
Hunan Steroids Chemicals Co Ltd, China. 
The obtained XRPD pattern (Figure 4.1) fits with the powder pattern of form I calculated 
from the reported structure. The DSC thermogram (Figure 4.2) shows an endothermic event at about 
217°C corresponding to the transformation of form I to the metastable form Il. Form 11 then melts at 
257 .9°C. The DSC data are consistent with literature results reported by Wens low et al. 1• 
The 13C CPMAS spectrum (Figure 4.3) is in agreement with the published spectra by 
Wenslow et a/.1 and Morzycki et al.2 Each non-equivalent carbon in the spectrum corresponds to one 
peak which agrees with the crystal structure of form I having one molecule in the asymmetric unit 
(Z'=1). The assignments of the chemical shifts for the obtained spectrum were adopted from the 
Morzycki et al. publication since the author found that the older assignments by Wens low et al. for C3 
and C20 were swapped (Table 4.1).This statement was a result ofthe assumption that C3 in both form 
I and li should have a closely similar chemical shift since the hydrogen bond lengths of the lactam 
group in the two forms are the same (2.85 A). The assumption was further supported by the fact that 
the lactam carbonyl in both forms is more involved in the hydrogen bonding than the amide carbonyl, 
which was confirmed by the hydrogen bond lengths. Hence C3 has to be in the higher frequency part 
of the spectrum compared to C202• The obtained spectrum is of a better quality than the ones in the 
literature since it was acquired on a 500 MHz (proton frequency) spectrometer while the spectra in the 
literature were acquired on 3002 and 400 1 MHz (proton frequency) spectrometers. Better resolution 
was obtained, especially in the CH2 region. Although our spectrum looks better resolved, the best line 
widths obtained were in the range of 15-20 Hz, while Wens low et al. reported having some peaks 
with line widths of 5Hz1• The quadrupolar effect of 14N nuclei on resonances of neighbouring 13C 
nuclei was less pronounced than the literature case since the sample was acquired at a higher magnetic 
field. Nitrogen-bonded carbons showed split 13C resonances in the literature data while in our case the 
peaks were only broadened, showing shoulders sometimes. 
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Figure 4.1. Rietveld fitting of the observed diffractogram with the calculated powder pattern of form I. 
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Figure 4.2. DSC thermogram obtained for form I at a heating rate of 1 °C/ min. 
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Molecular structure I. Finasteride 
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Figure 4.3. Obtained 13C CPMAS spectrum for form I. Asterisks represent spinning side bands. The 
spectrum was acquired for 40 ms with proton decoupling power of 63 kHz. 
10 
Table 4.1. Chemical shifts (oc/ppm) and their assignments for form I in the literature and in the obtained 
spectrum. 
Carbon Number Wenslow et a/. 1 Morzycki et a/.2 Obtained spectrum 
1 146.9 146.7 146.9 
2 126.6 126.4 126.9 
3* 163.3 168.8 169.3 
5* 60.1 59.9 60.6 
6 26.5 25.9 26.8 
7 30.6 30.5 30.6 
8 36.5 36.2 36.8 
9 47 .6 47.4 48 .0 
10 39.0 39.6 40.2 
11 21.5 21.5 21.9 
12 38.4 38.3 38.8 
13 43 .9 43.7 44 .3 
14 55.7 55.5 56.1 
15 25.6 25.5 26.0 
16 24.0 23 .8 24.3 
17 57.3 57.1 57.6 
18 14.9 14.6 15.2 
19 14.3 14.1 14.7 
20* 168.8 163.5 164.3 
22* 51.5 51.5 51.9 
23,24 28.9 28.6 29.3 
and 25 
*Showing quadrupolar effect due to bonding with nitrogen. 
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4.1.2 Form 11 
The sample was prepared (B# LBll 26) by dissolving about I g of form I in a solution of 
ethyl acetate containing water with a concentration of 24 mg/ mL. The solution was then maintained 
at ambient temperature with stirring for an hour. The solution was left to evaporate overnight and then 
the solid was dried in a vacuum oven for 6 hours at 80 °C. This methodology is an implementation of 
the method described in the patent by McCauley et a/.3. 
The solid was characterised by XRPD (Figure 4.4), 13C CPMAS (Figure 4.6) and DSC (Figure 
4.5); all data agree with the reported results in the literature. The XRPD pattern fits with the 
calculated powder pattern of form II but shows small differences due to preferred orientation of the 
microcrystallites. The DSC thermogram shows only one endothermic event at 257.8 °C, 
corresponding to the melting point of form JI. 
The 13C CPMAS spectrum obtained indicates that there are two molecules in the 
asymmetric unit as most carbons sites show split peaks. Again better resolution was obvious 
in the CH2 region presumably due to better dipolar decoupling. For example, carbons C16, 
C15 and C6 were reported1'2 (Table 4.2) to each have a single peak, but in the obtained spectrum 
four resolved peaks are seen. The extra peaks most likely correspond to splitting of the peak 
of C16 (Figure 4.6). Also, as in the case of form I, the quadrupolar effect on carbons bonded 
to nitrogen is less pronounced than in the literature spectra. 
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Figure 4.4. Rietveld fitting for the observed diffractogram with the calculated powder pattern of form 11. 
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Figure 4.5. DSC thermogram obtained for form 11 at a heating rate of I °C/ min. 
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Figure 4.6. Obtained 13C CPMAS for form 11. Asterisks represent spinning side bands. The spectrum was 
acquired for 40 ms with proton decoupling power of 63 kHz. 
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Table 4.2. Chemical shifts (Oc/ppm) and their assignments for form 11 in the literature and in the obtained 
spectrum. 
Carbon Number Wenslow et a/.1 Morzycki et a/.2 Current work 
1 150.1/151.6 149.9/151.4 150.4/151.9 
2 123.0 122.8 123.3 
3 169.4 169.2 169.7 
5 59.2/60.4 59.8 59.6/60.9 
6 25.9 25.3 26.6 
7 30.8/31.4 30.8 3l.l/3l.7 
8 35.3 35.0 35.6 
9 48.5/48.8 48.6 48.9/49.2 
10 39.9/40.3 39.7/40.0 40.3/40.6 
11 21.0/21.5 22.6 21.3/21.9 
12 37.4/38.4 38.3 37.7/38.7 
13 44.0 43.8 44.3 
14 56.7/57.8 56.5 57.1/58.1 
15 24.8 25.0 25.6 
16 23.6 24.0 24.0/25.2 
17 58/58.5 57.9 58.3/58.8 
18 13.1/l3.6 13.3/l2.9 13.5/13.9 
19 12.1/12.59 12.3/11.9 12.5/l2.9 
20 165.l/l64.4 164.8 164.9/l65.7 
22 50.8 50.7 50.9 
23,24 27.9/28.2 27.7/28.1 28.3/28.7 
and 25 
4.2 Finasteride Polymorphs Reported in the Patent Literature 
In this section, characterisation of polymorphs and crystalline forms reported in the patent 
literature will be presented. 
4.2.1 Form HI 
The patent for this claimed form is published in the US patent and trademark office4 and in 
the World Intellectual Property Organisation(WIPOi. A number of trials were carried out to prepare 
this form. The trials varied because of the number of solvent combinations listed in the patent. The 
general method used for the preparation of this form was as follows; 1 g of finasteride form I 
was dissolved in 3 mL of dichloromethane. 60-70% of the dichloromethane was evaporated at 40-
450C. The resulting solution was then saturated with about 10 mL of petroleum ether at 40-60 oc 
under stirring. The solution was concentrated at 60-65 oc for about 15 minutes. The solid was kept 
over night to dry. The resulting solid was then kept under vacuum at 65 oc for 30 minutes. Further 
drying was done in the oven at 80 oc for 12 hours. 
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4.2.1.1 Synthesis 
(i) Trial#l(B# LBl/26) 
1 g of finasteride form I was dissolved in 3 mL of dichloromethane. 60-70% of the 
dichloromethane was evaporated at 40-45°C. The resulting solution was then saturated with about 10 
mL of petroleum ether at 40-60 oc under stirring. The solution was concentrated at 60-65 oc for about 
15 minutes. The solid was kept over night to dry. The resulting solid was then kept under vacuum at 
65 oc for 30 minutes. Further drying was done in the oven at 80 oc for 12 hours. 
(ii) Trial#2(B# LBl/32) 
0.5 g of finasteride form I was dissolved in 1.5 mL of chloroform. 60-70% of the chloroform 
was distilled off at 60-70°C. The resulting solution was saturated with about 5 mL of petroleum ether 
at 60-65 oc under stirring. The solution was concentrated at 60-65 oc for about 15 minutes. The solid 
was kept over night to dry. The resulting solid was then kept under vacuum at 65 oc for 30 minutes. 
Further drying was done in the oven at 80 oc for 12 hours. 
(iii) Trial#3(B# LBl/34) 
The sample was prepared by mixing form I and a 1:1 solution of diethyl ether (replacing 
petroleum ether) and chloroform at 60°C. The resultant slurry solution was evaporated to dryness 
under ambient conditions overnight. A portion of the sample was taken for XRPD examination and 
the rest of the sample was subjected to drying under vacuum at 65 oc for 30 minutes. In both cases the 
sample was a microcrystalline powder, i.e. no big crystals were observed. 
(iv) Trial#4(B# LBl/35) 
The same methodology as in trial#2 was repeated to confirm the results. 
(v) Trial#S(B# LBl/36) 
0.5 g of form I was dissolved in 1.5 mL of chloroform and maintained for 10 minutes at about 
65-70 °C. The resulting mixture was left at ambient conditions over night to dry. The sticky solid 
produced was put in the vacuum oven for 30 minutes at 60 °C. A sample was taken at this step for 
XRPD examination (portion#!). Further drying was done in the oven at 80 oc for 12 hours (portion 
#2). 
(vi) Triai#6(B# LBl/36) 
The method in Trial #2 was repeated but with checking of the sample before and after the 
drying steps. The sample was left to dry overnight at ambient temperature and then the sample was 
characterised before being put in the vacuum oven. 
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4.2.1.2 Characterisation 
(i) Trial#l 
The examined XRPD pattern for trial #1(Figure 4.7) showed a mixture of forms I and II. 
Rietveld fitting was used to approximate the percentage of each phase in the powder (see the right top 
of Figure 4.7). Preferred orientation was observed at peaks of 28 values (13.9° and 19.0°), where the 
observed peaks (blue) are more intense than the calculated peaks (red). 
(ii) Trial#2 
Trial #2 was a repetition of trial #1 replacing dichloromethane with chloroform. The XRPD 
pattern (Figure 4.8) showed the sample to be a mixture of three forms. Peaks due to forms I and li fit 
with the calculated powder pattern (red trace Figure 4.8). Unfitted peaks cor~espond to the 28 values 
reported for form Ill in the patent (Table 4.3). 
The 13C CPMAS spectrum (Figure 4.9) was run to confirm the XRPD results and to extract 
the characteristic peak positions for form Ill. Peaks apart from those of the two known forms were 
labelled (Figure 4.9) and the chemical shifts were tabulated (Table 4.5). Looking at the carbonyl 
region in the spectrum, it may be concluded that this form has three molecules in the asymmetric unit. 
The peak at 63.7 ppm (green arrow in Figure 4.9) is not a fmasteride peak, i.e. the peak is due to a 
certain solvent. The solution-state 13C NMR was run in order to check this observation. Since 
petroleum ether is not miscible with chloroform, another solvent was used to run solution-state NMR. 
THF was found to be miscible with petroleum ether, hence deuterated THF was used. As expected, 
the corresponding 13C spectrum (Figure 4.10) showed a peak at 62.8 (labelled as solvent in Figure 
4.10). Solution-state 1H NMR (Figure 4.11) of the sample dissolved with solvents THF-d8 was run to 
check for extraneous peaks. The spectrum showed a moderately different spectrum than that of 
finasteride alone with some peak differences of impurities level. The presence of solvent(s) in the 
sample might be further concluded from the TGA loss (Figure 4.12) of 2.2 % observed at 64.3 oc 
though one cannot be sure from this evidence what the "solvate "is. The DSC (Figure 4.13) analysis 
for this sample did not show any special feature compared to that of form 11. 
(iii) Tria1#3 
As a consequence of the previous trial (trial #2), the solvate which is producing peaks 
corresponding to "form Ill" can be either a chloroform solvate or a petroleum ether solvate. To 
continue the investigation it was attempted to prepare a diethyl ether solvate. Diethyl ether was 
chosen because the extraneous peak found in both solid and solution states 13C NMR at about 63 ppm 
is close to the CH2 of diethyl ether, which should appear according to the tables at 65.9 ppm. 
The XRPD pattern (Figure 4.14) of a first portion fits with the calculated powder pattern of 
the known ethyl acetate solvate. The XRPD pattern (Figure 4.16) of the other portion (the dried one) 
fits with the calculated powder pattern of form JI. These results suggest that portion # 1 of the sample 
represents a solvate. This was further confmned by TGA. The TGA thermogram ofportion#1 showed 
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a mass loss of 17.9% at 72.6°C (loss expected due to diethyl ether is 16.6%) observed (Figure 4.15). 
This experiment suggests that diethyl ether is not the solvent included in trial #2.The dried solid 
(portion #2) was shown to be form 11 by XRPD (Figure 4.16), indicating that the solvate converts to 
the form 11 by heating the solid for 30 minutes at 65 °C. 
(iv) Trial#4 
The same methodology as in trial#2 was repeated to confirm the results. However, different 
results were obtained as the solid was found to be a mixture of forms I and 11 by XRPD (Figure 
4.17). Peaks at 29 values corresponding to the patented form Ill were not seen; hence, the 
methodology is non-reproducible, at least in my hands. 
(v) Tria1#5 
This sample was prepared to check the probability of having a chloroform solvate (rather than 
another solvate) which could be the claimed form Ill. 0.5 g of form I was dissolved in 1.5 mL of 
chloroform and maintained for 10 minutes at about 65-70 °C. The resulting solution was evaporated at 
ambient conditions over night. The sticky solid produced was put in the vacuum oven for 30 minutes 
at 60 oc. A sample was taken at this step for XRPD examination (portion#1). Further drying was done 
in the oven at 80 oc for 12 hours (portion #2). 
The first portion was showed to be a mixture of forms I and 11 by XRPD (Figure 4.18). The 
solid stayed as a mixture (Figure 4.19) of the two forms after the final drying step with increase in the 
percentage of the metastable form 11 (Figure 4.19) from 70.9 % to 84.6%. 
Neither a chloroform solvate was produced nor was the produced solid the claimed form Ill. 
(vi) Trial#6 
A solvate was produced giving an XRPD pattern which (Figure 4.20) fits with the ethyl 
acetate solvate (as in the diethyl ether case). Drying in the vacuum oven produced 51.4 % of form 11 
(Figure 4.21). Also as in the case of trial #5, further heating in the last step produces form 11 
(metastable), this time producing pure form 11 at the end (Figure 4.22). 
Table 4.3. 29 values of form Ill trial #2 compared with the reported values 
Peak number 20 values/ d-spacings Corresponding 20 values/ d-spacings 
of numbered peaks of form nr·5 
1 5.4116.36 5.3/16.67 
2 10.7/8.29 10.7/8.29 
3 13.7/6.50 13.6/ 6.55 
4 16.2/ 5.52 16.11 5.56 
5 18.3/ 4.90 18.2/4.93 
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4.2.1.3 Summary 
A summary of the trials carried out and results is shown in Table 4.4. 
T bl 4 4 a e . . summary o t e trta s carne f h . l 'd f ll out o owmg "f or m Ill" 
Sample ID Method of preparation Characterization Conclusion 
Trial# I Using dichloromethane as the XRPD show a mixture Preparation of form Ill was 
(B# LB l/26) halogenated solvent of form I and 11 not achieved. 
Trial#2 Using chloroform as the XRPD and uc CPMAS Form Ill was identified 
(B# LBl/32) halogenated solvent show that the sample is a with 28 values as reported in 
mixture of three forms the patent 
(I,II, and Ill) 
Trial#3 From diethyl ether and isolating Form XRPD, the sample Diethyl ether solvate was 
(B# LBl/34) samples from before and after before drying is prepared (only small 
drying apparently a diethyl portion) and characterized by 
ether solvate and after XRPD and TGA. 
the drying procedure the 
sample transformed into 
the metastable form 11 
Trial#4 Same methodology used for XRPD show a mixture The results for trial#2 were 
(B# LBl/35) trial #2 was repeated of form I and 11 not reproduced. 
Trial#5 From Chloroform alone XRPD show a mixture It is not possible to have a 
(B# LBl/36) of form I and 11 chloroform solvate (the 
sample was shown to be 
sticky and after drying it was 
shown to be a mixture of 
form I and 11). 
Trial#6 From petroleum ether without From XRPD, portion #I A petroleum ether solvate 
(B# LBl/36) drying the sample in the oven is a solvate and can be prepared 
(portion # 1) and after drying in portion#2 is a mixture 
the oven (portion#2) ofform I and form 11 
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Figure 4.7. Rietveld fitting for the observed diffractogram of trial# I with the calculated powder pattern of 
forms I and 11. 
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Figure 4.8. Diffractogram of form Ill trial#2 sample (blue trace). The red trace is the calculated powder 
pattern for forms I and 11. Numbered peaks do not correspond to those of any of the two forms. 
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form I 
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Figure 4.9. Obtained 13C CPMAS for form Ill trial #2(black trace). Red and blue traces correspond to the 
spectra of forms I and 11, respectively, in the mixture. Asterisks represent spinning side bands. The 
spectrum was acquired for 40 ms with proton decoupling power of 58 kHz. 
T bl 4 5 Ch . I h.f ~ h d .. k . h a e .. enuca s 1 ts or t e tstinct pea s m t e spectrum o ff or m Ill . I #2 tna 
Number Chemical shift/~pm Number Chemical shift/ ppm 
I 11.8 21 48.7 
2 13.0 methyl 22 49 .5 C9 
3 13.7 groups 23 50.0 
4 14.1 24 51.2 C22 
5 22.6 25 55.7 
6 22 .9 C6,Cil,CI5 26 56.5 Cl4 
7 25.0 and Cl6 27 57.0 
8 25.6 28 57.7 Cl7 9 29.5 t-butyl 29 58.1 
10 29.9 group 30 60.3 CS 11 32.2 C7 31 61.4 
12 35.7 C8 32 63.7 Solvent 13 36.2 33 124.0 C2 
14 38.2 34 148.6 
15 39.1 C10,C12 35 150.6 Cl 16 39.5 36 152.5 
17 39.8 
and C13 
37 166.3 
18 41.2 38 167.4 
19 44.0 C13 39 169.4 C3 and C20 20 44.9 40 171.0 
41 172.6 
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Figure 4.10. Obtained 13C NMR of finasteride form Ill trial #2 sample dissolved in THF-D8. The peak 
due to the included solvent is labelled as "solvent". 
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Figure 4.11. Obtained 1H NMR offinasteride form Ill trial #2 sample dissolved in THF-D8. Peaks apart 
from THF or finasteride are labelled by a question mark"?". 
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Figure 4.12. TGA thermogram for form Ill trial #2. 
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Figure 4.13. DSC thermogram for form Ill trial #2 at a heating rate of l 0 C/ min. 
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Figure 4.14. Diffractogram for form Ill trial#3 portion one (blue trace). The red trace is the calculated 
powder pattern for the ethyl acetate solvate. 
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Figure 4.16. Diffractogram for form Ill trial#3 portion two (blue trace). The red trace is the calculated 
powder pattern for form 11. 
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Figure 4.17. Diffractogram for form Ill tria1#4 (blue trace). The red trace is the calculated powder 
pattern for forms I and 11. 
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Figure 4.18. Diffractogram for form Ill trial#5-portion#1 
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Figure 4.19. Diffractogram for form Ill trial#5-portion#2 (blue trace). The red trace is the calculated 
powder pattern for form I and 11. 
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Figure 4.20. Diffractogram for form Ill trial#6-portion#l (blue trace). The red trace is the calculated 
powder pattern for the ethyl acetate solvate. 
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Figure 4.21. Diffractogram for form Ill trial#6-portion#2 (blue trace). The red trace is the calculated 
powder pattern for the ethyl acetate and form 11. 
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Figure 4.22. Diffractogram for form ill tr ial#6-portion#3 (blue trace). The red trace is the calculated 
powder pattern for the ethyl acetate solvate. 
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4.2.2 Form Hl 
This form is reported in the patent6 to be prepared from different alcohols. Each alcohol 
mentioned was tried individually in this research in order to reproduce the Hl form. The form was 
only characterised by XRPD in the patent. 
4.2.2.1 Synthesis 
(i) Trial#l(B# LBl/30) 
0.5 g offinasteride form I was dissolved in 2 mL of ethanol, heated to 55°C and maintained at 
this temperature for 15 minutes. The solution was left to evaporate over night. 
(ii) Trial#2(B# LBl/34) 
0.5 g of Finasteride form I was dissolved in 2 mL methanol, heated to 55°C and maintained at 
this temperature for 15 minutes. The solution was cooled toRT and then left to evaporate at RT 
overnight. 
(iii) Trial#3(B# LB1/37){1PA solvate} 
0.5 g of finasteride form I was dissolved in 2 mL lP A, heated to 60°C and maintained at this 
temperature for 1 hour. The solution was cooled in the fridge overnight. The solution was then left to 
evaporate at RT for 24 hours. A highly crystalline sample was produced (sufficient for single crystal 
XRD studies). 
4.2.2.2 Characterisation 
(i) Trial#l 
The XRPD (Figure 4.23) shows clearly that the sample is of form I. 
(ii) Trial#2 
This time the XRPD pattern obtained (Figure 4.24) shows that the sample is ofform 11. 
(iii) Trial#3{IPA solvate} 
Although the obtained XRPD pattern (Figure 4.25) is different to that of forms I and 11, it is 
not in agreement with the pattern of the claimed Hl form. The observed XRPD is closely similar to 
the calculated powder pattern of the ethyl acetate solvate, with some differences due to preferred 
orientation. At this stage and with only the XRPD examination, the identity of the solid is not known. 
The 13C CPMAS NMR spectrum of this sample (Figure 4.51) is different from those of any of the 
known forms, including that of the ethyl acetate solvate. In fact the sample was found to be an lP A 
monohydrate solvate (see section 4.4). A distinct DSC thermogram ( Figure 4.61) was 
observed for this solid form. The TGA thermogram shows a loss of 9.8% in two stages between 40°C 
and 1 00°C, indicating the presence of the solvent in the solid. Further structural characterisation of the 
solvate is included later in sections 4.4.2 and 4.4.3. 
-52-
Chapter 4: Finasteride Solid Forms 
4.2.2.3 Summary 
A summary of the trials carried out and results is shown in Table 4.6. 
T bl 4 6 S a e .. ummary o t e o t e tna s carne ou o owmg e c a1me or m fh fh '1 'd tfll th I . d "Hl f " 
Sample ID Method of preparation Characterization conclusion 
Trial#\ From ethanol From XRPD form I was None of the trials match with 
(B# LBI /30) 
Trial#2 From methanol 
(B# LBl/32) 
Tria\#3 From IPA 
(B# LB 1/34) 
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Figure 4.23. Diffractogram for form Hl trial#l (blue trace). The red trace is the calculated powder 
pattern for form I. 
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Figure 4.24. Diffractogram for form HI trial#2 (blue trace). The red trace is the calculated powder 
pattern for form 11. 
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Figure 4.25. Diffractogram for the IPA solvate (blue trace). The red trace is the calculated powder 
pattern for the ethyl acetate solvate. 
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4.2.3 Form H2 
This form was reported in the patent to be prepared from a solution in dioxane by 
Parthasaradhi et a/. 6 in 2004 (the same patent as the Hl form). It was claimed to be a new polymorph 
suitable for pharmaceutical formulation. The form was characterised only by XRPD. Since a dioxane 
solvate was already reported in 2002 by Morzycki et a/.2, the form was suspected not to be a true 
polymorph. The form was prepared as per the patent to be checked by full characterisation (solid-state 
NMR, thermal analysis and XRD). 
0.5 g of finasteride of form I was dissolved in 2.5 mL of dioxane, heated to 80°C and 
maintained at this temperature for 15 minutes. The solution was cooled to 25 oc within 3 hours. The 
resulting solution was maintained at ambient temperature over night to evaporate. A highly crystalline 
sample was produced. 
The XRPD pattern obtained (Figure 4.26) matches the one reported in the patent, with relative 
different intensities due to preferred orientation. The pattern is different than those of forms I and 11 
but fits closely with the ethyl acetate solvate calculated powder pattern. Hence, Parthasaradhi et a/.6 
seem to have erroneously considered this form as a new one because its XRPD pattern was not 
compared with those of the published ethyl acetate solvate7• As in the case of the IPA solvate, the 
XRPD examination is not enough to determine the identity of the solid. 
The 13C CPMAS NMR spectrum of this sample (Figure 4.52) is different to those of the 
known forms, including the ethyl acetate solvate. The peaks due to dioxane were assigned in the 13C 
CPMAS (Figure 4.52) according to the 13C solution-state NMR spectrum. Peaks due to dioxane were 
also assigned in the 1H MAS NMR spectrum (Figure 4.56). A distinct DSC thermogram (Figure 4.62) 
was observed for this solid form. The TGA thermogram shows a loss of 13.2% at about 60 °C, 
indicating the presence of the solvent in the solid. Further structural characterisation of the solvate is 
included later in sections (4.4.2 and 4.4.3). 
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Figure 4.26. Diffractogram for the dioxane solvate (blue trace). The red trace is the calculated powder 
pattern for the ethyl acetate solvate. Some differences appear due to preferred orientation. 
4.3 Finasteride Solvates Reported In the Scientific Literature 
4.3.1 Acetic Acid Solvate( Finasteride-Acetic Acid Complex7) 
The solid was prepared as per the methods published in the scientific 7 and patent4'5 literature. 
In both cases a gluey solid was produced, but this matter was not discussed in the literature. Further 
drying of the product in the vacuum oven at 50 oc for an hour produced a highly crystalline solid 
which then became examinable. 
The crystals were crushed under liquid nitrogen for XRPD examination. The observed pattern 
(Figure 4.27) shows that the bulk sample is of the acetic acid solvate in the literature. The 13C CPMAS 
spectrum observed (Figure 4.28) agrees with the crystal structure of this form as it shows there is one 
molecule in the asymmetric unit. Chemical shift assignments were made according to the assignments 
for form I, which also has one molecule in the asymmetric unit. Peaks due to acetic acid were 
assigned according to the known solution-state shifts. The 1H MAS NMR spectrum (Figure 4.29) 
shows a characteristic peak due to the acetic OH proton (compared with solution state) while there is 
some uncertainty about the acetic acid methyl group. The peak at -0 .1 ppm is still not identified. It 
may be due to the acetic acid methyl group although the expected chemical shift in the solution state 
is 2.0 ppm. 
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Figure 4.27. Diffractogram for the dioxane solvate (blue trace). The red trace is the calculated powder 
pattern for the acetic acid solvate. 
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Figure 4.28. Obtained 13C CPMAS spectrum for the acetic acid solvate. Asterisks represent spinning side 
bands. The spectrum was acquired for 40 ms with proton decoupling power of 100kHz. 
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Figure 4.29. Obtained 10 MAS NMR spectrum for the acetic acid solvate sample. MAS rate is 20 kHz. 
4.3.2 Ethyl Acetate Solvate( Bis-Finasteride Monohydrate Ethyl Acetate 
Clathrate7) 
This solid was reported by W awrzycka et al. 7 in 1999. Later it was rep01ted to be prepared by 
a different methodology in the patent literature4•5. 
Firstly, the patent methodology was tried (B# LBl /35) by preparing a slurry of a 0.5 g of 
finasteride form I in 1.5 mL of an ethyl acetate, THF and water mixture such that the ratio of ethyl 
acetate: THF: water is 1:1 :~0.1, then heating the resultant slurry to a temperature of 60°C for about 20 
minutes. The slurry was then cooled in the fridge over night. The solid was left to dry at RT. 
The observed XRPD pattern (Figure 4.30) fits closely with the calculated powder pattern of the ethyl 
acetate solvate. To help assigning the 13C CPMAS spectrum (Figure 4.31 ), the solution-state 13C NMR 
(Figure 4.32) was obtained. Peaks other than those of fmasteride were found to be characteristic for 
ethyl acetate and, unexpectedly, THF. The 13C CPMAS spectrum was then found to be a mixture of 
two spectra corresponding to the ethyl acetate and a THF solvate (see section 4.3.24.4.3) but it is not 
known whether the THF and ethyl acetate are in the same crystals or if the sample is a mixture of 
crystals. There were no big crystals in the sample enough to check with single crystal XRD. 
The DSC (Figure 4.33) shows a different thermogram from those of any of the anhydrous 
forms. The TGA thermogram (Figure 4.34) showed a loss of 10.8% at about 55°C, thus confirming 
the presence of solvents. Quantitative solution-state 1H NMR was done to calculate water and solvent 
molar ratios in the sample. First the 1H NMR spectrum was run for the sample (Figure 4.35) and then 
for a sample spiked with small drops of water (Figure 4.36) in order to determine the water peak 
position. Integrals of solvent peaks were tabulated (Table 4.7) and the molar ratios were calculated. 
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The water peak was shifted (to around 1.9 ppm) after spiking indicating its presence. The molar ratios 
agree with the 13C CPMAS spectrum as the THF solvate spectrum was the major component in the 
mixture. Only traces (impurity) of ethyl acetate were detected. The ratio of the ethyl acetate was 
calculated based on the CH30 (4.12 ppm) since it is resolved, unlike other resonances (1.25 and 2.04 
ppm). In the case of THF, the resonances gave a ratio of 0.4. The water peak showed a ratio of 0.6, 
which is close to the ethyl acetate case, where it is expected to be 0.5 from the crystal structure. The 
theoretical TGA loss expected from a ratio of 0.5 of each of water and THF (without counting the 
traces of ethyl acetate) is 10.8% which is in agreement with the observed value (10.8%). 
fJ) 
Table 4.7. Quantitative analysis obtained from solution-state 1H NMR for the "ethyl acetate" 
solvate sample prepared according to the patent recipe. 
Chemical shift/ oH Solvent/ assignment Integral Molar ratio/ finasteride 
3.7 
1.85 
4.12 
1.9 
THF/ CH20(multiplet) 
THF/ CH2(multiplet) 
Ethyl acetate/ CH20(quartet) 
water 
1.56 
1.73 
0.09 
1.19 
0.4 
0.4 
0.05 
0.6 
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Figure 4.30. Diffractogram for the "ethyl acetate" solvate sample prepared according to the patent recipe. 
The red trace is the calculated powder pattern for the ethyl acetate solvate. 
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Figure 4.31. Obtained 13C CPMAS spectrum for the "ethyl acetate" solvate sample prepared according to 
the patent recipe. Asterisks represent spinning side bands. The spectrum was acquired for 40 ms with 
proton decoupling power of 55 kHz. 
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Figure 4.32. Obtained 13C NMR spectrum of the "ethyl acetate" solvate sample prepared according to the 
patent recipe and dissolved in CDCI3,. 
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Because the results for the first sample, prepared according to the patent method, were 
anomalous, another sample was prepared (B# LB1/39) according to the scientific literature reference7• 
0.5 g finasteride form I was dissolved in ethyl acetate and a few drops of water. The resulting mixture 
was heated to a temperature of 55°C for about 20 minutes. The mixture was then cooled toRT and left 
to evaporate over night. 
The observed XRPD pattern (Figure 4.37) fits with the ethyl acetate calculated powder 
pattern, as in the case of the first trial, but this time showing a 13C CPMAS spectrum (Figure 4.38) 
which corresponds to that of a pure ethyl acetate solvate. As expected from the crystal structure of the 
ethyl acetate in the literature, the spectrum indicates that there are two molecules in the asymmetric 
unit. ·Chemical shift assignments were based on the solution-state assignments. The ethyl acetate 
peaks in the 13C CPMAS spectrum were distinguished by direct pulse (DP) 13C NMR (Figure 4.39). 
The most prominent peaks in the DP spectrum arise form the mobile methyl carbons, which have 
relatively short relaxation times. Somewhat unusually, signals from some quaternary carbons appear 
weakly, presumably because their relaxation times are shortened by their proximity to the methyl 
groups.The 1H MAS NMR spectrum (Figure 4.40) shows peaks due to the solvent. 
Quantitative solution-state 1H NMR shows that there is a molar ratio of 0.4 and 0.5 of ethyl 
acetate and water, respectively, to finasteride (Table 4.8). Theoretically, from the crystal structure, the 
ratios should be 0.5 for each. The theoretical TGA % loss expected is 10.6% (based on 0.4 and 0.5 
ratios) which is similar to the result obtained (10.3%) within experimental error (Figure 4.41). The 
obtained DSC thermogram (Figure 4.42) is somewhat different from that of the first trial (THF and 
ethyl acetate mixture). The DSC and TGA data have not been reported in the literature. 
Table 4.8. Quantitative analysis obtained from solution-state 18 NMR for the ethyl acetate solvate. 
Chemical shift/ Ou Solvent/ assignment Integral Molar ratio/ finasteride 
4.12 
1.9 
Ethyl acetate/ CH20(quartet) 0.86 
water 2.05-1.10= 0.95 
0.4 
0.5 
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Figure 4.37. Diffractogram for the ethyl acetate solvate sample. The red trace is the calculated powder 
pattern for the ethyl acetate solvate. 
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Figure 4.38. Obtained 13C CPMAS spectrum for the ethyl acetate solvate. Asterisks represent spinning 
side bands. The spectrum was acquired for 40 ms with proton decoupling power of 55 kHz. 
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Figure 4.40. Obtained 1H MAS NMR spectrum for the ethyl acetate solvate sample. 
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Figure 4.42. DSC thermogram obtained for the ethyl acetate solvate at a heating rate of 1 °C/ min. 
The idea of having an ethyl acetate solvate without the existence of water was checked by 
preparing a sample like the ethyl acetate sample but without adding water (B# LBl /39). 0.5 g of 
finasteride form I was dissolved in ethyl acetate. The resulting mixture was heated to a temperature of 
55"C for about 20 minutes then cooled to RT and kept to evaporate over night 
The XRPD pattern (Figure 4.43) shows that the sample is a mixture of three forms; ethyl 
acetate solvate, form I and form II. The results were also confirmed in the 13C CPMAS spectrum 
(Figure 4.44). It can be concluded that water stabilises the ethyl acetate solvate (including water) and 
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decreasing the concentration of water in the sample initiates the formation of the other anhydrous 
forms (I and Il). 
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Figure 4.43. Diffractogram for the "ethyl acetate solvate" sample prepared without water. The red trace 
is the calculated powder pattern for the ethyl acetate solvate, form and form n. 
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Figure 4.44. Obtained 13C CPMAS spectrum for the "ethyl acetate solvate" sample prepared without 
water. Asterisks represent spinning side bands. The spectrum was acquired for 5 ms with proton 
decoupling power of 55 kHz. 
4.4 Newly prepared Finasteride Solvates 
The synthesis and characterisation of a newly prepared solvates are included in the section. 
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4.4.1 Synthesis 
4.4.1.1 lFinasteride THF Hydrate Solvate {Bis-Finasteride Mono-Tetrahydrofuran 
Monohydrate} 
0.5 g of finasteride form I was dissolved in THF. The resulting solution was heated to a 
temperature of 55 T for about 20 minutes, then was cooled to RT and kept to dry overnight (B# 
LBl/39). Large colourless crystals of prismatic shape suitable for single crystal XRD examination 
were produced. 
Another sample (sample#2) was prepared to investigate the effect of adding water (not 
excluding it as in the ethyl acetate case) on the preparation of the THF solvate (B# LBl/39). 0.5 g 
finasteride form I was dissolved in THF and a few drops of water. The resulting solution was heated 
to a temperature of 55 OC for about 20 minutes, then cooled to RT and kept to evaporate overnight. 
Finer crystals were produced compared to the first trial. 
4.4.1.2 Finasteride IPA Hydrate Solvate { Bis-Finasteride Mono-Isopropanol 
Monohydrate} 
0.5 g of finasteride form I was dissolved in 2 mL lP A, heated to 60 oc and maintained at this 
temperature for 1 hour. The solution was cooled in the fridge overnight. The solution was then left to 
evaporate at RT for 24 hours. Large colourless crystals of prismatic shape suitable for single crystal 
XRD examination were produced. 
4.4.1.3 Finasteride Dioxane Hydrate Solvate {Bis-Finasteride Mono-Dioxane 
Monohydrate} 
0.5 g of finasteride of form I was dissolved in 2.5 mL of dioxane heated to 80 oc and 
maintained at this temperature for 15 minutes. The solution was cooled to 25 oc within 3 hours. The 
resulting solution was maintained at ambient temperature over night to evaporate. Large colourless 
crystals of prismatic shape crystals suitable for single crystal XRD examination were produced. 
4.4.2 X-ray Characterisation 
4.4.2.1 XRPD characterisation 
Samples of the IPA and dioxane solvates were ground prior XRPD examination to minimise 
the preferred orientation effect. The grinding was done under liquid nitrogen, except for the THF 
solvate sample, to prevent phase transformation. The crystals of the THF solvate sample were crushed 
smoothly (not ground). The corresponding XRPD patterns for the lP A and dioxane solvates were 
shown previously (Figure 4.25 and Figure 4.26 in sections 4.2.2 and 4.2.3 respectively). The XRPD 
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pattern for the THF solvate and THF solvate sample #2 (with additional water) are shown below 
(Figure 4.45 and Figure 4.53 respectively). 
All prepared samples have XRPD patterns which fit reasonably with the calculated powder 
pattern for the ethyl acetate solvate. The differences due to preferred orientation between the observed 
and the calculated powder patterns for all prepared samples varied from one solvate to another. Other 
differences were seen in the case of the THF solvate sample at low 28 values. These relatively larger 
differences are likely to be due to the high crystallinty of the sample (not ground). However, the 
obtained XRPD patterns for all prepared solvates, along with that of the ethyl acetate solvate, are 
indistinguishable. More strictly speaking, no information can be concluded from the XRPD about the 
included solvent. 
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Figure 4.45. Diffractogram for the THF solvate sample. The red trace is the calculated powder pattern for 
the ethyl acetate solvate. 
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Figure 4.46. Diffractogram for the THF solvate (prepared with additional water). The red trace is the 
calculated powder pattern for the ethyl acetate solvate. 
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4.4.2.2 Single crystal XRD characterisation 
Table 4.9 summarises the crystallographic data for the newly prepared finasteride solvates. 
The solvates are isomorphous (also with the ethyl acetate solvate); all having orthorhombic lattice 
symmetry, P212121 space groups, two molecules in the asymmetric unit and an empirical formula of 
bis-finasteride monohydrate monosolvate (Figure 4.47). Moreover, the solvent molecules are highly 
disordered inside a channel along the a crystallographic axis (Figure 4.48). Clearly the channel 
structure allows ready ingress of molecules of moderate size and it is anticipated that many other 
solvate hydrates may be prepared. The water molecules appear to be essential to maintain the open 
channel structure. 
Although the dioxane solvate was mentioned in the scientific literature2, full characterisation 
was not done (only FT-IR and 13C CPMAS NMR). Hence, the author was not aware of the presence 
of water in the solvate. 
The two molecules (referred to as molecule 1 and molecule 2, containing carbon atoms 1-25 
and 26-50, respectively) inside the asymmetric unit are connected with strong intermolecular 
hydrogen bonding, from the lactam side of ring A, forming a dimer (Figure 4.49). The NH group in 
the lactam side is a hydrogen bonding donor while the carbonyl group of the lactam side is an 
acceptor. Such hydrogen bonding was reported 1 for all finasteride forms in the literature where as the 
amide NH was reported to be uninvolved in hydrogen bonding due to the steric effect of the tert-butyl 
group. 
Figure 4.50 shows the network formed between water and finasteride molecules in the 
dioxane solvate. It is also representative of the IPA, ethyl acetate and THF solvates. The water 
molecules in finasteride monohydrate solvates act as bridge, through intermolecular hydrogen 
bonding, linking finasteride molecule dimers. Water is involved in three hydrogen bonds; being a 
hydrogen bond donor to lactam group 0 atoms on two finasteride molecules below, and a hydrogen 
bond acceptor from the peptide N atom from the finasteride molecule above it (Figure 4.50). 
Whilst the water molecules are shown to be strongly fixed in the crystal structure, the solvent 
disorder in the solvates is severe; hence the dioxane, lP A and THF molecules could not be located as 
recognizable molecular entities in the Fourier difference maps. A similar degree of solvent disorder 
was found in the isomorphous ethyl acetate solvate7• As a consequence of that NMR and other 
techniques were consulted (see the next section 4.4.3) in order to quantify the solvents. 
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Table 4.9. Obtained single XRD data for the prepared finasteride hydrate solvates 
Composition Finasteride Finasteride Finasteride 
dioxane solvate IPA solvate THF solvate 
Empirical Formula 2 C23H36N202 · 2 C23H36N202 · 2 C23H36N202 · 
H20 · C4Hs02 H20 · C3Hs01 H20 · C4H80 1 
Gross formula CsoHs2N207 C49Hs2N206 CsoHs2N206 
Molecular Weight (amu) 823.2 795.2 807.2 
Crystal dimensions (mm3) 0.12 X 0.16 X 0.28 0.16 X 0.20 X 0.20 0.20 X 0.20 X 0.20 
Crystal system orthorombic orthorombic orthorombic 
Space group P212121 P2 12121 P212121 
a (A) 8.1110(7) 8.1132(3) 8.1317(3) 
b(A) 18.0856(16) 17.9012(8) 17.7767(7) 
c (A) 35.512(3) 35.6948(15) 35.7349(15) 
V(A3) 5209.4(8) 5184.2(4) 5165.7(4) 
z 4 4 4 
Z' 2 2 2 
T(K) 120 120 120 
Calculated Density (g/ cm-3) 1.050 1.019 1.038 
,u (mm-1) 0.07 0.07 0.07 
Number of observed reflections 6298 3772 3529 
Number of parameters refined 595 528 524 
R;m (%) 3.5 2.2 1.5 
R (%) for I > 2 cr 11.3 7.1 8.1 
wR(%) 25.5 17.0 19.1 
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C!24l 
Figure 4.47. Molecular structure and atom numbering scheme for finasteride dioxane hydrate solvate. 
The atomic displacement parameters are drawn at 50% probability. Disordered solvent and hydrogen 
atoms have been omitted from the picture for clarity. The same numbering scheme was used for the 
isomorphous IPA and THF solvates. 
Figure 4.48. Packing in bis-finasteride monohydrate monosolvates viewed along the a crystallographic 
axis. 
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Figure 4.49. Dimers formed between crystallographically independent finasteride molecules through N-
H ... O hydrogen bonding 
Figure 4.50. Hydrogen bonding between water and finasteride molecules in bis-finasteride monohydrate 
solvates. 
4.4.3 NMR and Thermal Analysis Characterisation 
The 13C CPMAS NMR spectra for the IPA, dioxane, THF and THF-water (sample#2) 
solvates are shown in Figure 4.51 , Figure 4.52 and Figure 4.53, respectively. The spectra confmned 
the uniqueness of each form by the presence of peaks assigned to the solvents. The assignments were 
based on solution-state chemical sltifts for the lP A and dioxane solvates. In the case of the THF 
solvate, a 13C direct pulse (DP) NMR spectrum (Figure 4.54) was obtained to determine the mobile 
component peaks. The 13C CPMAS spectrum for the THF sample with additional water (sample#2) 
was found to be the same as that of the ftrst sample of the THF solvate (without water in the 
preparation). It can be concluded that the addition of water does not affect the formation of the THF 
solvate. 
Distinct 1H MAS NMR spectra for each of prepared solvates were observed, as shown in 
Figure 4.55, Figure 4.56 and Figure 4.57. The peaks due to the solvents were assigned according to 
solution-state results. 
Since the solvents cannot be quantified from single crystal XRD analysis, quantitative 
solution-state 1H NMR experiments were carried out for each of the prepared samples. A water 
spiking procedure was used for the determination of the water peak in the spectra. In cases where the 
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water peak is overlapped with other genuine finasteride peaks, the quantitation was done by 
subtractions (after spiking integral minus nonnal spectrum integral). 
In the case of the IPA solvate (Table 4.1 0), the calculated ratio of water can be inaccurate 
since the signals for the OH protons from IPA and water are overlapped. The lP A peak at 1.2 ppm 
was not used in the calculation because of interference from finasteride peaks in that region. As per 
the ratio of 0.5 for both IPA and water the expected TGA loss is 9.5% which is close to the observed 
loss of9.8% (Figure 4.58). 
Table 4.10. Quantitative analysis obtained from solution-state tu NMR for the IPA solvate. 
Chemical shift/ 011 Solvent/ assignment Integral Molar ratio/ finasteride 
4.04 
~ 1.9 
IPA/ CH(septet) 
Water+ OH ofiPA(broad) 
0.55 
1.24-0.55=0.69* 
0.55 
0.3 
The water peak was overlapped with peaks of finasteride. After spiking of water the peak was resolved, 
hence the integral was subtracted. 
For the dioxane hydrate solvate case (Table 4.11 ), as per the ratios of 0. 7 of dioxane and 0.4 
of water, the expected TGA loss is 15.6% while the observed loss is 13.2% (Figure 4.59). The% loss 
expected according for a 0.5 ratio of both components is 12.5. 
Table 4.11. Quantitative analysis obtained from solution-state tu NMR for the dioxane solvate. 
Chemical shift/ 011 Solvent/ assignment Integral Molar ratio/ finasteride 
3.70 dioxane/ CH2(septet) 5.9 0.7 
1.9 water 2.10-1.36= 0.74* 0.4 
The water peak was overlapped with peaks offinasteride. After spiking of water the peak was resolved, 
hence the integral was subtracted. 
In the same manner, the THF solvate was examined (Table 4.12). As per the ratios calculated, 
the TGA loss is expected to be 14.1% while the observed loss is 13.0 %(Figure 4.60). However, the 
theoretical %TGA loss for a 0.5 ratio ofboth components is 10.8. 
Table 4.12. Quantitative analysis obtained from solution-state tu NMR for the TUF solvate. 
Chemical shift/ o11 Solvent/ assignment Integral Molar ratio/ finasteride 
1.85 THF/ CH2(multiplet) 2.62 0.7 
3.74 THF/ CH20(multiplet) 2.61 0.7 
1.9 water 2.36-1.10= 1.26* 0.6 
The water peak was overlapped with peaks of finasteride. After spiking of water the peak was resolved, 
hence the integral was subtracted. 
From the above, it is realised that the observed TGA loss% for both the IPA solvate and the THF-
ethyl acetate solvate (ethyl acetate sample #1) is close, within experimental error, to the expected loss 
calculated on the bases of the 1H NMR data and a 0.5 ratio of solvent and water (Table 4.13). In the 
ethyl acetate hydrate solvate case, the loss expected for a 0.5 ratio is higher by about 2% than the 
observed and that calculated according to the 1 H NMR data. On the other hand for the dioxane and 
THF solvates, the loss expected according to the 1H NMR data is higher than the others because the 
ratio of dioxane was calculated to be 0.7 rather than 0.5. The diethyl ether solvate is shown to be out 
of the trend as the expected loss% calculated on a 0.5 ratio is significantly lower than the observed 
-74-
Chapter 4: Finasteride Solid Forms 
loss but the observed loss is almost similar to the loss due to 2 molecules of diethyl ether and one 
molecule of water (2:2: 1 of finasteride: diethyl ether: water) which is 18 .2%. 
It is worth mentioning here that the molecular weight range for all the examined solvates is between 
(60.1-88.1 gl mol), where the molecular weights of dioxane and ethyl acetate are similar (88.1 0 and 
88.11 gl mol, respectively) and the molecular weights of THF and diethyl ether are close (72 .11 and 
74.0 gl mol, respectively). 
Table 4.13. TGA data comparison for the prepared finasteride solvates. 
sample Observed Expected TGA loss% as per Expected TGA loss% as 
Diethyl ether solvate 
Ethyl acetate sample# I 
(THF +ethyl acetate) 
Ethyl acetate solvate 
IPA solvate 
Dioxane solvate 
THF solvate 
TGA loss% solution-solution-sate per 0.5 ratio of solvent 
17.9 
10.8 
10.3 
9.8 
13.2 
13.0 
experimental results and water 
10.5 
10.6 
9.3 
15 .6 
14.1 
10.9 
10.8(THF + water alone) 
12.5 
9.5 
12.5 
10.8 
A distinct DSC thermogram was obtained for each solvate ( Figure 4.61 , Figure 
4.62 and Figure 4.63). The thermograms obtained for the dioxane and THF solvates (Figure 4.62 and 
Figure 4.63) were similar to that of the ethyl acetate solvate except that the broad-minor endothermic 
event is shifted to higher temperatures (from about 45.8 oc to 76-77 °C). An interesting DSC 
thermogram for the IPA was obtained where two endothermic events seen at 68.8 oc and 102.2 °C. It 
can be concluded for this result that the escape of IPA and water from the crystals is not simultaneous 
which means that a purely hydrate form may intervene and thus can be synthesised. The same 
conclusion can be obtained from the TGA thermogram (Figure 4.58) of the IPA where two merged 
steps were observed. To check this phase transformation, variable temperature experiment either on 
the solid-state NMR or on the XRPD should be carried out. 
C3 
C2 
C20 C1 
70 60 
C14 
C9 
50 
C10 
40 15dppm 
C8 
C23.C24 
& c 5 
30 
C15 
C18 
C19 
20 10 
Figure 4.51. Obtained 13C CPMAS spectrum for the IPA solvate. Asterisks represent spinning side 
bands. The spectrum was acquired for 40 ms with proton decoupling power of 55 kHz. 
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Figure 4.52. Obtained 13C CPMAS spectrum for the dioxane solvate. Asterisks represent spinning side 
bands. The spectrum was acquired for 40 ms with proton decoupling power of 58 kHz. 
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Figure 4.53. Obtained 13C CPMAS for the THF solvate. Asterisks represent spinning side bands. The 
spectrum was acquired for 40 ms with proton decoupling power of 55 kHz. 
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70 60 50 40 
'6d ppm 30 
Figure 4.54. Obtained 13C direct pulse (DP) NMR spectrum for the THF solvate. 
shown for peaks due to the THF solvate. 
CH3+ finasteride 
OH 
CH 
40 20 0 -20 -40 
8/ ppm 
20 10 
Chemical shifts were 
Figure 4.55. Fast MAS 1H NMR spectrum obtained for the IPA solvate. The MAS rate is 20kHz. 
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~finasteride 
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0 
40 20 0 
-20 -40 
of ppm 
Figure 4.56. Fast MAS 1H NMR spectrum obtained for the dioxane solvate. The MAS rate is 20 kHz. 
CH 2 + flnasteride 
0 
40 20 0 -20 -40 
01 ppm 
Figure 4.57. Obtained 1H MAS NMR spectrum for the THF solvate sample. The MAS rate is 8.5 kHz. 
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Figure 4.58. TGA thermogram for the IPA solvate at a heating rate of 2°C/ min. 
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Figure 4.59. TGA thermogram for the dioxane solvate at a heating rate of 2°C/ min. 
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Figure 4.60. TGA thermogram for the THF solvate at a heating rate of 2°C/ min. 
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Figure 4.61. DSC thermogram obtained for the IPA solvate at a heating rate of l 0 C/ min. 
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Figure 4.62. DSC thermogram obtained for the dioxane solvate at a heating rate of I °C/ min. 
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Figure 4.63. DSC thermogram obtained for the THF solvate at a heating rate of 1 °C/ min. 
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4.5 Characterisation of form X 
An unknown sample was shown, by 13C CPMAS NMR (Figure 4.65) and XRPD (Figure 4.64), 
to be a mixture of form I, form II and an additional phase. No information is available about the 
preparation of this sample except that the sample was stored for several years at RT. Peaks matching 
those of the reported "form Ill" in the patent are found in the observed pattern (Table 4.14) of this 
sample, though some of the peaks are overlapped with the calculated peaks of both forms I and Il. 
This agreement in 28 values is the same as in the case of the prepared form Ill trial#2. Nevertheless, 
the 13C CPMAS NMR spectra for the two samples are different. The 13C CPMAS NMR spectrum for 
this new form (form X) suggests that it has one molecule in the asymmetric unit. Consequently, the 
13C chemical shifts of form X were compared with form I since both are similar in this aspect. This 
form is either a new anhydrous form or a new hydrate form since the solution-state 13C NMR 
spectrum of this sample showed no extra peaks. The existence of water in the sample (hydrate) was 
not fully investigated. The solution-state 1H NMR spectrum did not show any clear contribution of 
water. 
The following were found when comparing form I and form X chemical shifts (Table 4.15) 
with the solution-state chemical shifts; Cl, C2, C3, C7, C8, Cl8 and C20 have the same chemical 
shifts difference trend though variations of more than 1 ppm are seen between the two forms. Among 
these carbons C3 is more deshielded in form X than for form I which indicates that the carbonyl group 
of the lactam side in form X is forming a stronger hydrogen bonding than form I. Also, C20 is 
deshielded more in form X which might suggest that the peptide group side is involved in hydrogen 
bonding, unlike the case of form I. Cl 0 has a similar chemical shift difference in both cases, while 
Cll, C13, C14 and C17 are steady in all three cases (along with the solution-state shifts). C9, C12 and 
the t-butyl group carbons are more deshielded in form X than form I. In fact, the t-butyl group carbons 
in form I have a similar chemical shift for that of the solution state, which further suggests the 
involvement of the peptide group in hydrogen bonding. On the contrary; CS, C19 and C22 are more 
deshielded in form I than in form X. However, for the last two sets of carbons form X has a similar 
trend as in the prepared solvates case (Table 4.18) where the chemical shifts are more deshielded than 
form I. Consequently, it can be suggested that although the prepared solvates and form X are different 
in number of molecules in the asymmetric unit, they might be similar in the hydrogen bonding profile. 
For C6, C15 and Cl6 the comparison was not established since they were not assigned properly for 
form X due to lack of resolution. 
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Figure 4.64. Diffractogram for the mixture sample containing form X (blue trace). The red trace is the 
calculated powder pattern for forms I and 11. Numbered peaks match with the reported peaks for the 
claimed "form Ill". 
Table 4.14. Distinct 29 values of form X compared with the reported values. 
Peak number 29 values/ d-spacings 
of numbered peaks 
I 5.4/ 16.36 
2 10.7/ 8.29 
3 16.2/ 5.52 
4 17.3/ 5.18 
5 18.3/ 4.90 
6 23.1 / 3.92 
C31!r 
160 
form I 
form 11 
crude 
60 
C17 C14 C22 
50 
140 
C13 
C9 
C2~ 
l! 
Corresponding 29 values/ d-spacings 
of form 104'5 
5.3/ 16.67 
10.7/ 8.29 
16.115.56 
17.2/ 5.21 
18.2/ 4.93 
23 .0/ 3.94 
* 
QAA A.. 
* 
a+ 
120 100 80 
N 
u 
C10 ea 
C18 
40 30 20 
8c1 ppm 
C19 
Figure 4.65. 13C CPMAS spectrum for the crude sample (including form X). Green arrows are used to 
show the distinct peaks due to form X. Asterisks represent spinning side bands. 
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Table 4.15. 13C chemical shifts (ocf ppm), giving a comparison between solution-state, form I and form X. 
The differences between solution state and the two other forms solid-state chemical shifts are given in 
parentheses (o solution state- o solid state). Differences smaller than 0.5 are omitted from the table. 
Carbon number Solution State (CDC13) Form I Form X 
151.11 146.9(4.2) 148.6(2.5) 
2 123.25 126.9(-3.7) 126.1(-2.9) 
3 166.89 169.3(-2.4) 171.1(-4.2) 
5 59.88 60.6(-0.7) 60.3 
6 26.12 26.8(-0.7) 25.2 or 25.8 
7 29.66 30.6(-0.9) 31.2( -1.5) 
8 35.54 36.8(-1.3) 36.2(-0.6) 
9 47.82 48.0 48.9(-1.1) 
10 39.62 40.2(-0.6) 40.3(-0.7) 
11 21.48 21.9 21.7 
12 38.66 38.8 39.7(-1.0) 
13 44.16 44.3 44.5 
14 55.87 56.1 55.8 
15 24.51 26.0(-1.5) 25.2 or 25.8 
16 23.46 24.3( -0.8) 25.2 or 25.8 
17 57.67 57.6 57.3 
18 13.53 15.2( -I. 7) 14.8( -1.3) 
19 12.24 14.7( -2.5) 12.5 
20 171.84 164.3(7.6) 166.4(5.4) 
22 51.33 51.9( -0.6) 51.2 
23,24 29.28 29.3 30.1 (-0.8) 
and 25 
4.6 Comparative study on finasteride solid forms 
The solvent molecules in all solvates were severely disordered inside channels of the crystal 
structure showing large indistinguishable electron density distribution. However, the 13C CPMAS 
NMR spectra show considerable differences (Figure 4.66). This fact shows that solid-state NMR can 
be significantly more sensitive than diffraction experiments, especially when rapid motion or disorder 
occurs in part of a crystal unit cell. 
The differences in chemical shifts of form I from these of the solution state are in agreement 
with those reported in the literature1.2. The significant differences found for carbons sited at ring A 
were attributed to the involvement of the ring with strong hydrogen bonding which comes from the 
lactam group side1.2• The differences in the assignment of C3 and C20 between solution and solid 
states were explained2 by the fact that the carbonyl carbon is deshielded the more it is participating in 
hydrogen bonds8. 
Peaks due to C9, C19 and the t-butyl group do not show big large differences in chemical shifts 
among the hydrate solvates but they show variable patterns, where the degree of splitting of the two 
peaks changes. In a similar manner the C14 and C17 peaks occasionally show four peaks (2 peaks 
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each) or tend to show triplets( IPA and THF). C22 show two peaks, with the first one being broader. 
Large variations in the chemical shifts of Cl in all solid forms are found, specifically between from I 
and 11 about 3 ppm, but in the solvates case it is even more deshielded (about 2 ppm difference from 
form 11). C3 is more deshielded in the solvates case than for the two anhydrous forms. This change is 
due to the bigger contribution of the lactam carbonyl in hydrogen bonding in the solvates since they 
form additional hydrogen bonds with the water molecules. C20 is found to be more deshielded in all 
solvates than for the two anhydrous forms, where it is known that the carbonyl (from the peptide side) 
is not contributing to hydrogen bonding. As in the crystal structure of the hydrate solvates, it is 
expected that C20 is deshielded because of hydrogen bonding with bridging water molecules. Most 
other peaks have close chemical shifts for all the hydrated solvates. 
Preliminary proton spin-lattice relaxation measurements were done on the solvates and on form 
11 (anhydrous). The experiments were carried out at ambient temperature using the 5 mm probe, 
except for the acetic acid solvate where the 2.5 mm probe was used. The relaxation parameters (T1) 
are, within experimental error, the same for both solvent and "host" Table 4.20. The values are also 
indistinguishable for the solvated and anhydrous forms (form 11). This suggests that the relaxation is 
driven by reorientation of the methyl groups rather than by solvent dynamics. 
Stability and phase transformation of the prepared solvates are of interest. A variable (high) 
temperature experiment was performed on the dioxane solvate, probing the 13C CP MAS spectra 
(Figure 4.67). At each set temperature, the probe was left for 15 minutes for thermal equilibration and 
the 13C spectra were 10 minutes long. Saturation recovery experiments were performed at each 
temperature to calculate T1 relaxation coefficient under spinning and static conditions. The later 
relaxation experiments are not reported since the results were found to be not useful. However, the 
time spent at each temperature point was about 45 minutes. The temperature was increased as shown 
in Figure 4.67 and the 13C spectrum was checked in the end at ambient temperature. Phase 
transformation starts at 1 00°C to the anhydrous form I, and almost all of the dioxane solvate is 
transformed by 125°C. The water molecules seem to escape simultaneously with the dioxane since no 
intermediate (between the dioxane solvate and form I) finger print was observed. The post 13C 
spectrum indicated, as expected, that the transformation from the dioxane solvate to form I is 
irreversible. It was reported that form I undergoes transformation to form II at higher temperature 
(about 150 °C) 7 . It was also reported that form II can be prepared by sublimation of the ethyl acetate 
solvate at about 235 oc and thermal decomposition of the acetic acid solvate occurs at about 175 °C. 
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a e T bl 4 16 C rysta u h' d ograp1 1c ata on 
Form ID Form 11 form 0 1 
Formula C23H36N202 C23H36N202 
FW 372.6 372.6 
Lattice 
orthorhombic monoclinic Symmetry 
Space P2 12121 P2 1 group 
a (A) 6.437(1) 16.387(2) 
b (A) 12.712(1) 7.958(2) 
c (A) 25.929(1) 18.115(5) 
a_O 90 90 
{3C) 90 107.25(2) 
yC) 90 90 
z 4 4 
Z' 1 2 
Unit cell 
volume 2121.7(6) 2256(2) 
<A3) 
CSD code WOLXOK02, WOLXOK03, WOLXOKOI WOLXOKb 
Melting 253-256 253-256 Point ('C) 
a Obtained at low temperature XRD. 
b The XRD data was poor in this case 
acetic acid solvate 
ethyl acetate solvate 
THF solvate 
isopropyl alcohol solvate 
dioxane 
solvate 
70 
master. e so orms 'd lid f fi 
acetic acid ethyl acetate IPA 
solvate7 solvate7 Solvate• 
finasteride. 2finasteride. 2finasteride. 
CH3COOH H20.C4Hs02 H20. C3Hs0 
432.6 851.2 795.2 
monoclinic orthorhombic orthorhombic 
P2 1 P212121 P2 12121 
12.170(1) 8.173(31 8.1132(3) 
8.16521 (7) 18.364(6) 17.9012(8) 
13.577(1) 35.65(2) 35.6948( 15) 
90 90 90 
111.630(1) 90 90 
90 90 90 
2 4 4 
1 2 2 
1254.1 (2) 5350(4) 5184.17 
WOLXEA WOLXIE To be published 
255-257 252-255 257 
60 50 40 30 
Bel ppm 
Dioxane THF 
Solvate• Solvate• 
2finasteride. 2finasteride. 
H20. C4HsOz H20. C4HsO 
823.2 807.2 
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8.1110(7) 8.1317(3) 
18.0856(16) 17.7767(7) 
35.512(3) 35.7349(15) 
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90 90 
90 90 
4 4 
2 2 
5209.34 5165.65 
To be To be 
published published 
257 257 
20 10 
Figure 4.66. The 13C CPMAS spectra of finasteride solvates showing, the spectra are readily 
distinguished. The low field part of the spectra ( carbonyl region) are not shown. 
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Table 4.17. 1H NMR chemical shifts for examined finasteride solid forms. 
Sample Chemical shift 8cl assignment Line width at MAS 
pp m half height(Hz) condition 
IPA 1.4 Finasteride+ IPA CH3 279 20kHz at 
3.4 IPA-CH 203 2.5mm probe 
4.2 IPA-OH 160 
Dioxane 1.0 finasteride 730 
3.2 Dioxane-CH2 342 
Acetic acid -0.1 Acetic acid-CH3 126 
1.1 finasteride 473 
13.3 Acetic acid-OH 502 
THF solvate 1.8+ shoulder at~ 1.2 Finasteride+ THF-CH2 310 8.5 kHz at 
3.7 THF-CH20 170 5mm probe 
Ethyl acetate 1.2 Finasteride+ ethyl acetate- 299 
solvate CH3 
2.0 ethyl acetate-CH30 110 
4.2 CHz 204 
Form 11 1.2 finasteride 868 
Table 4.18. Obtained chemical shifts (Ocf ppm) for finasteride solid forms. The differences between 
solution state and solid state chemical shifts of form I are given in parentheses (0 solution state- o solid stare)· The 
differences smaller than 0.5 are not shown in the table. 
Carbon Solution Dioxane IPA THF Ethyl acetate Acetic acid State Form I Form 11 
Number (CDCI
3
) solvate solvate Solvate solvate solvate 
I 151.11 146.9(4.2) 150.4/151.9 152.5/153.5 154.0 b 153.5 b 152.8/ 153.7 153.0b 
2 123.25 126.9(-3.7) 123.3 122.1/122.7 122.0/122.6 122.1/122.8 122.3/122.87 120.9b 
3 166.89 169.3(-2.4) 169.7 170.5 170.9 171.0 171.0 170.1 
5 59.88 60.6(-0.7) 59.6/60.9 59.9/60.6 59.9/60.5 60.1160.8 60.JO/ 60.8 60.4 
6 26.12 26.8( -0.7) 26.6 27.0 27.1 27.2 27.1 25.6 
7 29.66 30.6(-0.9) 31.1/31.7 29.9/31.3 30.0/31.5 30.3/31.5 30.3/31.5 30.3 
8 35.54 36.8(-1.3) 35.6 34.9/35.7 35.1/35.8 35.2/ 35.9 35.1/35.9 35.0 
9 47.82 48.0 48.9/49.2 49.1 48.8/49.2 49.1/49.4 49.3 48.6 
10 39.62 40.2(-0.6) 40.3/40.6 40.0 40.3 40.3 40.3 40.0 
11 21.48 21.9(-0.5) 21.3/21.9 21.4b 21.4 b 21.6b 21.5/ 21.7 22.0 
12 38.66 38.8 37.7/38.7 37.3/38.4 37.5/38.2 37.5/38.5 37.5/38.6 36.8 
13 44.16 44.3 44.3 44.1 44.3 44.4 44.5 43.5 
14 55.87 56.1 57.1158.1 55.3/56.2 55.4/ 56.5 55.51 56.4 55.5156.2 54.7 
15 24.51 26.0(-1.5) 25.6 25.1/25.3 25.2/25.5 25.7b 25.3/25.7 25.2 
16 23.46 24.3(-0.8) 24.0/25.2 22.0/22.6 22.1122.7 22.3/22.9 22.3/ 23.0 22.6 
17 57.67 57.6 58.3/58.8 56.9/58.2 56.5/58.0 56.7/58.1 57.0/58.2 56.3 
18 13.53 15.2(-1.7) 13.5/13.9 13.2/13.6 13.7/ 13.4 13.4/ 13.9 13.5/13.9 12.8 
19 12.24 14.7(-2.5) 12.5/12.9 12.1/12.3 12.45 12.5 i 12.3/ 12.5 12.4 
20 171.84 164.3(7.6) 164.9/165.7 168.6,169.0 169.4 b 169.0b 168.8b 166.7 
22 51.33 51.9(-0.6) 50.9 50.2/50.9 50.2/50.9 50.3/50.9 50.2/ 51.1 50.0 
23,24 29.28 29.3 28.3/28.7 28.9/29.2 29.3/29.6 29.4/29.7 29.5 28.3 
and 25 
: broad peak 
i: intense peak 
s : small splitting 
0 
: overlapped by the CH2 of the ethyl acetate 
Underlined chemical shifts correspond to the chemical shifts assigned for two carbons 
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25°J 
70 
Table 4.19. 13C NMR chemical shifts corresponding to the solvent 
molecules in the examined finasteride solvates. 
Sample Chemical shift Bel ppm Assignment 
IPA 26.2 CH3 
63.8 CH 
Dioxane 67.5 CH2 
Acetic acid 20.7 CH3 
174.6 C=O 
THF solvate 26.5 CH2 
68.1 CH20 
Ethyl acetate 14.5 CH3 
solvate 20.5 CH30 
60.1 CH2 
169.2 C=O 
60 50 40 30 
Figure 4.67. 13 C CPMAS variable-temperature spectra of the dioxane solvate. 
WL_ 
20 10 
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Table 4.20. Proton relaxation measurements obtained under spinning. 
Solid form T 1/ (s) at ambient temperature' 
Dioxane 1.39 ±0.01 1.36±0.01 
solvate (CH2) ( finasteride) 
IPA solvate 1.08±0.02 1.10±0.02 1.13±0.01 
(CH) (OH) (finasteride+ CH3) 
THF solvate 1.15±0.01 1.15±0.01 
(CH20) ( finasteride+CH2) 
Ethyl acetate 1.23±0.01 1.22±0.01 1.20±0.01 
(CH2CH3) (CH30) (CH2CH3 + finasteride) 
Acetic acid 1.12±0.10 0.95±0.12 1.02±0.09 
solvate (OH) ( finasteride) (CH3) 
Form 11 0.92±0.01 
The errors reported in the table are statistical from the plots and the true errors are 
likely to be larger (general estimate± 5-10%). 
4. 7 Conclusions 
(i) The methodology reported for the preparation of form Ill is not reproducible, at least in my 
hands. It is possible that this "form Ill" is a solvate of a certain petroleum ether component. 
(ii) A diethyl ether solvate was prepared and characterised by XRPD. 
(iii) The claimed Hl form in the patent could not be reproduced; in fact each alcohol used leads 
to different forms. 
(iv) The characterisation of fmasteride solid forms in the patent by only XRPD led to some 
deficiencies, while using solid-state NMR the solid forms are readily distinguished. 
(v) Three new hydrate solvates were prepared and characterised by XRD and NMR. The 
solvates were found to be isomorphous. Due to highly disordered solvent molecules the XRD 
analysis failed to give an estimate of the amount ofthe included solvent. However, NMR was 
successively used for this purpose. The data were also compared with the thermal analysis 
data (TGA). 
(vi) A new unknown unsolvated sample was characterised by solid-state NMR. 
(vii) An unknown sample was shown, by 13C CPMAS NMR and XRPD, to be a mixture of 
form I, form 11 and a third new phase. This new form is expected to be either a new 
polymorph or a hydrate and it is probably closely related to "form Ill". 
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4.8 Future Work 
(i) Only a small portion of the diethyl ether solvate sample was prepared. The solvate is to be 
re-prepared and characterised properly by solid-state NMR. 
(ii) Study solvents dynamics inside the solvates by 2H NMR using deuterated samples. 
(iii) The two separated DSC events seen for the lP A solvate before melting suggest that a new 
form can be prepared which can be either a hydrate or an anhydrous lP A solvate. 
(iv) As all prepared solvates contained water molecules, trials following a hydrated form are to 
be carried out. 
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Chapter 5: Solid Forms of Androsterone 
5.1 Introduction 
Androsterone, C19H300 2; 5a-androstane-3a-ol-17-one, is a male sex hormone (androgen) 
with functional prostate property. It was proved to be a metabolite of testosterone 1 and has recently 
been studied as a contributory factor to prostate cancer. 
Androsterone was chosen for this research as it was structurally a very simple steroid for which 
literature references suggest the possibility of different solid forms. 
Molecular structure of androsterone 
5.2 Literature Review on Androsterone Solid Forms 
5.2.1 Androsterone Form 1 
Form 1 is the anhydrous form which has been reported in the literature three times. First, the 
crystal structure (CSD code ANDOON03) was reported by Bemal et al. 3 in 1936. Later (in 1966) the 
crystal structure was redetermined by High et al. 4• Recently, the crystal structure was redetermined 
again by low temperature single-crystal XRD by Hulme et al.5• The unit cell parameters and space 
groups from these studies are shown in Table 5.1. High et a/.4 note several unusual geometrical 
features present in their structure, all of which take more conventional values in the redetermination 
by Hulme et al. 5 • The features are torsion angles between the angular methyl groups, hydrogen bond 
angle and length and C-C and C-H bond lengths. The differences between the two structural 
determinations were attributed5 to the difference in temperature at which the data sets were collected 
and the superior nature of the determination on a modem diffractometer. 
Form 1 crystals were grown by slow evaporation from a solution of ether in the first two 
references3•4 while Hulme et al. 5 reported their crystals to be grown from slow evaporation from a 
solution of absolute ethanol. 
Form 1 has a melting point of 186"C and it has two symmetry-related molecules (Z=2) in the 
unit cell bonded head to tail by hydrogen bonding connecting the hydroxyl group (ring A) with the 
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carbonyl group (ring D) of a second molecule, see Figure 5.1. The crystal structure has a hydrogen 
bonded chain structure, with the chains propagated parallel to the b crystallographic axis by the 21 
screw axis, see Figure 5 .1. 
Table 5.1. Unit cells reported for androsterone form 1. 
Reference CSD Code Space Group a (A) b (A) c (A) ~ e> {3 (0 ) y e) 
Bemal et a/3 , 1936 ANDOON03P2 1 9.45 7.70 11.95 90 Ill 90 
High et a/.4 , 1966 ANDOON P2 1 9.56(2) 7.90(3) 11.78(2) 90 111.37(3) 90 
Hulme et a/. 5, 2006 P2 1 9.4045(9) 7.9586(8) 11.6746(12) 90 111.274(2) 90 
t The crystal structure is not yet included in the database. 
Figure 5.1. Androsterone form I crystal structures viewed along the crystallographic b axis . 
. ·· 
Figure 5.2. Androsterone form 1 crystal structures showing the hydrogen bonding (dotted lines) chain 
along the crystallographic c axis. 
- 93-
Chapter 5: Solid Forms of Androsterone 
5.2.2 Androsterone Form 2 
The unit cell of androsterone form 2 has been reported on two occasions (see Table 5.2), 
although in neither paper was the full structure determined. 
Table 5.2 unit cells reported for androsterone Form 2. 
Reference CSD Code Space Group a (A) b (A) c (A) a e) 
Banerjee et al. 6,1971 ANDOON02 P2 11m 7.20 10.40 22.00 90 100 90 
Bouche et al. 7, 197 6 ANDOON01 P2t 7.30 10.40 22.20 90 100 90 
A hydrate of androsterone was identified8 in 1968 by thermal microscopy which desolvated at 80°C. 
Banerjee et a/. 6 proposed the possibility of "a second polymorph" of androsterone, and reported a 
unit cell different to that of form 1, see Table 5.2. The crystals that gave this unit cell were grown 
from a solution of ether. Bouche et at identified that the crystals grown from ether and dried 
exhibited an event in the DSC trace at approximately 165°C, which was then followed by the same 
form 1 melting event at 183-186°C. They identified this as a phase change from a new "Form 2" to 
Form 1. They also reported that this change could be initiated by grinding. They also suggest this 
change occurs spontaneously, but slowly, when the "Form 2" crystals are left to stand for a period of 
time. Because this phase change occurs well above the desolvation temperature of the hydrate, there 
is no suggestion that this phase change is related to the hydrate. This subtle phase change was not 
observed by either thermal microscopy or infrared spectroscopy. The thermal behaviour (DSC 
events) of this new form did not change even after drying the crystals under vacuum for 24 hours. 
Powder diffraction was used to provide a unit cell reported as" form 2", which on the one hand is 
different from that of form 1 and the hydrate identified by thermal microscopl and on the other 
hand concurred with the unit cell published by Banjeree et al. 6 for his proposed form 2, see Table 
5.2. 
The recent work by Hulme et a/. 10 (next section) shows that this form cannot be reproduced 
and the unit cell parameters reported correspond to those of a different form (a hemihydrate). 
5.2.3 Androsterone Hemihydrate10 
Kuhnert-Brandstatter et al. 9 first identified a hydrate of androsterone by thermal microscopy, 
desolvating at 80°C. Bouche et al. 7 replicated the desolvation of the hydrated form first identified by 
Kuhnert-Brandstatter et al. 9 at 80°C. In this case the crystals were grown by evaporation from 70% 
ethanol solution at room temperature. Recently, large plate crystals grown from a solution of 
androsterone in wet ethanol were found to have similar unit cell parameters (Table 5.3) as 
reported for form 26·7 (Table 5.2). However, it was reported by Hulme et a/. 111 that the structure with 
this unit cell is a hemihydrate, with two androsterone molecules and a water molecule in the 
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asymmetric unit. They believe it is likely to be the "hydrate" identified already in the literature6'7 
which desolvates at 80°C and melts at about 185°C (melting point of form 1 ). 
Table 5.3. Unit cell of androsterone hemihydrate. 
Space Group a (A) b (A) c (A) a (D) {:J (D) y (D) 
Hulme et al. 5 P2 1 7.4288(8) l 0.289(1) 22.174(2) 90 97.553(2) 90 
The water molecules form three strong intermolecular hydrogen bonds between three 
androsterone molecules; being a donor for two androsterone molecules from their ring D carbonyl 
group sides and an acceptor from a third molecule from the hydroxyl group side of ring A, see 
Figure 5.4. The water molecules form another two weak hydrogen bonds of C-H ... 0 type (C65-
H65B ... 091 and C16-H16A ... 091). The two independent androsterone molecules are connected 
head-to-tail (ring A and ring D) by intermolecular hydrogen bonds 051-H51...02. The water 
molecules were found to lie inside a channel along the a crystallographic axis (Figure 5.5). 
Thermal analysis for androsterone hemihydrate showed that the dehydration takes place 
between 70-115 oc (shown by the DSC event) along with a mass loss of 3.2% (shown by TGA). 
These data are close to the dehydration temperature reported in the literature7·9 and the calculated 
mass loss of a hemihydrate (3%) respectively. The DSC data reported for the hemihydrate form 
indicate that it transforms to form 1 after dehydration, which was also reported for the hydrate form 
in the literature7• It was also reported that there is a small endotherm at 150°C between the 
desolvation and melting point events which was suggested to be the event reported by Bouche et 
aC. The phase transformation to the anhydrous form 1 was further confirmed by variable 
temperature XRPD, though the there was no evidence of phase transformation at 150°C as seen by 
DSC 10• The latter DSC event was suggested to be "a subtle relaxation in the crystal structure of the 
newly dehydrated phase". 
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Figure 5.3. Molecular structure and atom numbering for the androsterone hemihydrate asymmetric 
unit. 
I 
~-
Figure 5.4. Hydrogen bonds in the androsterone hemihydrate crystal structure 10 090 represents a water 
oxygen. 
Figure 5.5. Crystal packing for androsterone hemihydrate, with the view along the a crystallographic 
axis showing water molecules inside channels. 
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5.3 Materials Studied 
-Form I : A sample of androsterone form I was provided courtesy of Dr. R. W. Lancaster. Another 
sample of androsterone form I was obtained from Sigma-Aldrich. 
-Androsterone hemihydrate: A sample was provided courtesy of Dr. R. W. Lancaster. Other samples 
were prepared as per the literature10 and found to be of the same form. 
-"Form 2": I 50 mg of androsterone form I was dissolved in diethyl ether and heated until saturation. 
The solution was kept to evaporate slowly at room temperature (B# LBll I3).The analysis of the 
sample by both XRPD and 13C CPMAS showed that it is identical to form I, which is consistent with 
the work by Hulme et al. 10 where they could not reproduce form 2. 
5.4 Characterisation of Androsterone Form 1 
The sample from Sigma-Aldrich was examined by XRPD and found to be of pure form I 
(Figure 5.6). The sample contains large crystallites; hence a portion of the sample was crushed 
before examination. However, some differences are still found between the calculated and observed 
powder pattern indicating the presence of severe preferred orientation. The sample was examined on 
a glass slide which is responsible for the broad hump in the base line of the observed pattern. 
The purity of the sample was further confirmed by the 13C CP MAS NMR spectrum (Figure 
5.7). The spectrum shows peaks due to only one form and a single peak is observed for each carbon 
expected from the crystal structure of form I (Z'= I) . The chemical shift assignments appearing in the 
spectrum will be explained in section 5.6.2. The two samples mentioned in section 97 were found to 
be identical by comparing their 13C CP MAS NMR spectra. 
500 - d9_01386.raw:1 form_1 100.00% 
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fJ) 200 
c 150 
:::J 
0100 
() 50 . 
Q ··~--~~--~--
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-150 ·~ --y-~--~~~~~~~~~~~~~~~~~~~~~~~~~ 
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Figure 5.6. Rietveld fitting of the observed diffractogram of form I with the calculated powder pattern. 
The sample was smoothly crushed and examined on a glass slide. 
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Figure 5.7. The 13C CP MAS NMR spectrum for androsterone form 1. The spectrum was acquired for 
40 ms with proton decoupling power of 58 kHz. 
5.5 Characterisation of Androsterone Hemib.ydrate 
The sample obtained from Dr. Lancaster was examined by XRPD as is (without grinding or 
crushing) and showed several differences (Figure 5.8) between the observed and calculated patterns. 
As in the case of the form 1 sample, such differences are due to the large crystallites of the sample, 
which results in preferred orientation. Since the hemihydrate form undergoes transformation to form 
1 by heat10, grinding was performed under liquid nitrogen. Consequently, the differences in the 
Rietveld fitting were minimised to a remarkable extent (Figure 5.9). 
The 13C CPMAS NMR readily distinguishes between the two forms (form 1 and the 
hemihydrate form). Clear differences between the two spectra were observed (Figure 5.10). The 
obtained spectrum of the hemihydrate was consistent with the crystal structure since nearly all non-
equivalent carbons showed two peaks, indicating that the hemihydrate form has two molecules in the 
asymmetric unit (Z'=2). The spectrum of the hemihydrate form also shows minor peaks that 
correspond to form 1 peaks, indicating that the sample examined contains impurities of form 1. The 
peaks observed in the CH2 peaks region (25-35ppm) were quite broad due to the low dipolar 
decoupling power used. However, the decoupling power was not increased further since the 
acquisition time was long (75 ms), thus potentially leading to over-heating of the probe. 
A variable-time XRPD was carried on androsterone hemihydrate although a variable-
temperature (VT) XRPD was already done by Hulme et a/. 10• However, different results were 
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obtained in terms of the stability of the form. The hemihydrate form was found to be unstable at 
room temperature whereas in the literature it was found to be stable up to higher temperatures (full 
transformation took place between 65-130°C). The transformation to form 1 occurred within 24 
hours at 25°C. Figure 5.11 shows data sets collected every 14 minutes. Quantitative Rietveld 
analysis (Figure 5 .12) shows the kinetics of form 1 formation . 
The sample subjected to VT XRPD in the literature was not ground at all , whereas in my variable 
time experiment the sample was ground under liquid nitrogen. Hence, the instability could be 
attributed to either the fine particle size of the sample or the act of grinding. 
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Figure 5.8. The Rietveld fitting of the observed diffractogram for the hemihydrate form with the 
calculated powder pattern. The sample was examined as received on a silicon slide. 
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Figure 5.9. The Rietveld fitting of the observed diffractogram of the hemihydrate form with the 
calculated powder pattern. The sample was examined on a silicon slide after grinding under liquid 
nitrogen. 
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Figure 5.10. The 13C CPMAS NMR spectrum for androsterone hemihydrate. Peaks due to form I are 
assigned by "1". The spectrum was acquired for 75 ms with proton decoupling power of 56kHz. 
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Figure 5.11. Variable time XRPD monitoring for the hemihydrate form. Peaks due to hemihydrate (H) 
and form 1(1) are labelled. 
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Figure 5.12. The hemihydrate form transformation to form 1 by time at 25 °C. Initially, the sample 
contained 41.7% of the hemihydrate form and 58.3% of form 1. The scans were recorded every 14 
minutes. The data were fitted with the exponential function y= y0+ A0exp (-kt). 
5.6 13C Chemical Shift Assignments of Androsterone Solid 
Forms 
The solid-state assignments are done on the basis of the solution-state results. The latter 
assignments were made in the literature 11 in 1977 but the authors assigned two carbons to the same 
chemical shift (ClO and C16) due to lack of resolution. Consequently, the solution-state 13C NMR 
spectrum of androsterone was re-examined. The two unresolved peaks were separated in the 
obtained spectrum. The following section illustrates the experiments carried out to fully assign the 
peaks. 
5.6.1 Solution-state 13C Chemical Shift Assignments 
Figure 5.13 shows the androsterone 13C NMR spectrum. 2D NMR experiments were used to 
assign the chemical shifts in the range of 35-36 pp m (including the resolved peaks of C 10 and C 16). 
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' 65 60 55 50 45 40 35 30 25 20 15 pp m 
Figure 5.13. Androsterone solution-state 13C NMR spectrum. 
5.6.1.1 20 NMR (HMBC, HSQC and NOESY) 
As seen in Table 5.4, carbons 8, 10 and 16 are indistinguishable. However, CIO is 
quaternary, which can be spotted from the HSQC spectrum (36.5 ppm), see Figure 5.14. The other 
two carbons are of CH2 type. In the NOESY spectrum, the proton at C3 correlate with protons on C2 
and C4 (Figure 5.15) and the latter protons (at C2 and C4) correlate with C4 (36.0 ppm) in the 
HMBC spectrum (Figure 5.16), leaving the carbon at 36.1 ppm to be Cl6. Cl6 can also be 
confirmed by its correlation, in the HSQC and HMBC spectra, with the deshielded proton (the 
quartet at about 2.5 ppm), which in turn correlates with the carbonyl (Cl7) in the HMBC (Figure 
5.17). Table 8 shows the new chemical shift assignments. 
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Table 5.4. Final 13C chemical shift assignments. 
Carbon Number Chemical shifts (oJ ppm) 
1.2 
1.4 
1.6 
1.8 
2.0 
2.2 
2.4 
2.6 
Cl9 11.4 
Cl8 14.1 
Cll 20.3 
Cl5 22.0 
C6 28.5 
C2 29.3 
C7 31.1 
Cl2 31.8 
Cl 32.4 
C8 35.3 
C4 36.0 
Cl6 36.1 
ClO 36.5 
CS 39.4 
CI3 48.1 
Cl4 51.7 
C9 54.7 
C3 66.7 
Cl7 221.0 
C16 C4 CB 
C10 
'~ 
:b,~ 
~ 
tE35 
36 35 34 33 
C1 C12 C7 
~ 
i§? 
&~ 
~~~;>s 
R.:JO <ii:S 
32 31 
F1 (ppm) 
C2 C6 
<€~ 
~ 
30 29 28 27 
Figure 5.14. Androsterone HSQC spectrum, showing that CIO does not correlate with any proton. 
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Figure 5.15. Androsterone NOESY spectrum, showing that the proton at C3 (4.1 ppm) correlates with 
protons apart from CI6 protons (1.5-2.0 ppm). 
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Figure 5.16. Androsterone HMBC spectrum (zoomed-in scale}, showing that C4 does not correlate with 
protons which correlate with the protons at C3 in NOESY. C16 correlates with the deshielded proton at 
CI6. 
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Figure 5.17. Androsterone HMBC spectrum showing that protons at C16 correlate with C17 (carbonyl). 
5.6.2 Solid-state 13C Chemical Shift Assignments 
The 13C CPMAS spectra (Figure 5.7 and Figure 5.10 of form 1 and the hemihydrate form, 
respectively) were assigned on the basis of the solution-state chemjcal assignments, dipolar 
dephasing and selective population inversion experiments. 13C chemical shifts from the solution state 
helped in the assignment of most of the peaks in the solid-state spectrum, with some uncertainty in 
the region between 28-40 ppm. The assignments were done for androsterone form 1 and after that 
the hemihydrate form was assigned (as far as possible) accordingly. Table 5.5 includes the 
assignments for androsterone form 1 and the hemihydrate form chemical shifts. 
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5.6.2.1 Dipolar Dephasing and Selective Population Inversion Experiments 
By using the dipolar dephasing experiment, which observes the methyl and quaternary 
carbons only, carbons C10, Cl3, C17, C18 and C19 were assigned easily (Figure 5.18). 
The spectra obtained from the Selective Population Inversion experiment differentiate between the 
CH2 and CH groups. The CH2 peaks disappear or become negative by increasing the inversion time 
(Figure 5.18 and Figure 5.19), leaving the other peaks positive, though CH peaks diminish in 
intensity. Very long inversion times will turn the CH peaks negative though the CH2 peaks are 
inverted faster. This was observed with 50 ~s inversion time; see C8, CS, C14, C9 and C3 in Figure 
5.18 as examples. 
Table 5.5. Solid-state13C chemical shift (oc/ ppm) assignments for androsterone forms .The differences 
between solution state and solid-state chemical shifts are given in parentheses (o solution-state- o solid state)· 
Carbon No. (carbon type) Solution-state Forml Hemihydrate form 
C19(CH3) 11.4 12.7 (-1.3) 11.7113.5 (-0.3/-2.1) 
C18(CH3) 14.1 14.9 (-0.8) 14.3115.6 (-0.2/-1.5) 
C11(CH2) 20.3 21.2 22.0(1.7) 
C 15(CH2) 22.0 21.2 22.0 
C6(CH2) 28.5 27.9 (0.6) 28.3 (0.2) 
C2(CH2) 29.3 29.7 (-0.4) 29.7 (-0.4) 
C7(CH2) 31.1 32.1 ( -1.0) 30.5 (0.6) 
C 12(CH2) 31.8 33.0 (-1.2) 32.4 ( -0.6) 
C1(CH2) 32.4 33.9 (-1.5) 34.0 (-1.6) 
C8(CH) 35.3 35.7 (-0.4) 35.8/36.2 (-0.5/-0.9) 
C4(CH2)a 36.0 b 37.2 (-1.5) 37.5 (-1.2) 
C16(CH2)a 36.1 b 37.4 (-1.4) 37.5 (-1.3) 
C10(C) 36.5 37.0 ( -0.5) 36.9 (-0.4) 
C5(CH) 39.4 39.7 (-0.3) 39.3/40.0 (0.1/-0.6) 
C13(C) 48.1 48.7 ( -0.6) 48.5/48.8 (-0.4/-0.7) 
C14(CH) 51.7 52.8 (-1.1) 52.8/55.0 (-1.1/-3.3) 
C9(CH) 54.7 55.7 (-1.0) 55.4/57.2 (-0.7/-2.5) 
C3(CH) 66.7 66.4 (0.3) 64.5/66.4 (2.2/0.3) 
C17(C=O) 221.0 223.9 ("2.9) 224.7/225.7 (-3.7/-4.7) 
a observed only as a negative peak in the Selective Population Inversion experiment. 
a very small resolution between the two peaks. 
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Figure 5.18. This shows 13C spectra of androsterone form 1 obtained with different "editing" pulse 
sequences. Dipolar Dephasing show quaternary and methyl carbons while Selective Population 
Inversion invert the CH2 peaks (null or negative according the inversion time). 
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Figure 5.19. This shows 13C spectra of the androsterone hemihydrate form obtained with different 
"editing" pulse sequences. Dipolar Dephasing show quaternary and methyl carbons while Selective 
Population Inversion invert the CH2 peaks (null or negative according the inversion time). 
5. 7 Conclusions 
A solution-state 13C NMR spectrum of better resolution, than that in the literature, was 
obtained and the chemical shifts were assigned properly by 2D NMR. Androsterone hemihydrate 
fotm and fonn 1 were identified by 13C CPMAS and their chemical shifts were assigned on the basis 
of solution-state chemical shifts and using special solid-state NMR pulse sequences (Dipolar 
Dephasing and Selective Population Inversion). Noticeable differences (> 1.0 ppm) in chemical shifts 
between the solution-state and form 1 are mostly related to carbons sited at rings A and D of 
androsterone. The carbons in these rings are expected to be the most affected by the head-to-tail 
hydrogen bonding; hence the effect on their chemical shifts. C4, ClO and C16 chemical shifts were 
found to be in a different order than for the solution-state, of which C4 and C16 have significant 
chemical shift changes (~ 1.2 ppm). Although C3 is strongly involved in hydrogen bonding in form 
1, the difference in chemical shift is small. In the case of the hemihydrate form, the difference is 
much clearer. On the other hand, the carbonyl (C17) is significantly deshielded in the solid-state. 
Carbons 11 and 15 show a single overlapped peak in the solid-state spectrum, though the peaks are 
separated in the solution-state. Other significant differences are found for some carbons not located 
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at either ring A or D. It is worth pointing out here that the two forms are of similar ring 
conformation, see Figure 5.20. 
The hemihydrate transformation to form 1 by time was monitored using XRPD. Such 
transformation was also encountered while running some solid-state NMR experiments, where peaks 
due to form 1 started to appear as function of time. 
Hemlhydrate form 
Figure 5.20. Androsterone form 1 and the hemihydrate form showing the similarity of the ring 
conformations. 
5.8 Future Work 
Preliminary 1H MAS NMR work on androsterone solid forms was canied out. Signals from 
neither hydrogen bonding nor the water molecule in the hydrate form were resolved, probably 
because of the low resolution (two broad lines) obtained. It is planned to record the 1H and 2H MAS 
NMR of samples of the hemihydrate, with deuteration of the water and exchangeable hydrogens, in 
order to study molecular dynamics. 
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